4-aminoquinazoline derivative compounds and uses thereof

A 4-aminoquinazoline derivative compound targets PIKfyve and PIP5K1C to inhibit SARS-CoV-2 entry and enhance PARP inhibitor sensitivity in resistant tumors, addressing treatment challenges for both viral infections and cancer.

WO2026235510A1PCT designated stage Publication Date: 2026-11-12KOREA RES INST OF CHEM TECH +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096706
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for SARS-CoV-2 infections lack effectiveness, particularly in severe cases, and PARP inhibitor-resistant tumors exhibit resistance to existing therapies, necessitating new strategies to target genomic instability and viral entry pathways.

Method used

Development of a 4-aminoquinazoline derivative compound that acts as a dual inhibitor of PIKfyve and PIP5K1C, inhibiting SARS-CoV-2 infection by blocking ACE2-mediated endocytosis and targeting HR pathways in cancer cells, enhancing sensitivity to PARP inhibitors.

Benefits of technology

The compound effectively inhibits SARS-CoV-2 infection and induces apoptosis in PARP inhibitor-resistant tumors by reducing key HR proteins, offering a novel therapeutic approach for both viral infections and cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096706_12112026_PF_FP_ABST
    Figure KR2026096706_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a 4-aminoquinazoline derivative compound or a pharmaceutically acceptable salt thereof, and an antiviral agent and a pharmaceutical composition for treating cancer or tumors, each comprising same. It was confirmed that the 4-aminoquinazoline derivative compound of the present invention inhibits the proteolytic activation of cathepsins regulated by PIKfyve, thereby inhibiting the essential step for the virus to escape from endosomes, and inhibits cellular entry of the virus by blocking ACE2-mediated endocytosis through PIP5K1C inhibition. In addition, the 4-aminoquinazoline derivative compound of the present invention increases the sensitivity of tumors to PARP inhibitors, and thus can be effectively used for treating PARP inhibitor-resistant tumors.
Need to check novelty before this filing date? Find Prior Art

Description

4-Aminoquinazoline Derivative Compounds and Uses thereof

[0001] The present application claims priority based on Korean Patent Application No. 10-2025-0059364 filed on May 7, 2025, and all contents disclosed in the specification and drawings of said application are incorporated by reference into the present application.

[0002] The present invention relates to 4-aminoquinazoline derivative compounds and their uses, and more specifically, to the use of 4-aminoquinazoline derivative compounds as antiviral agents and for the treatment of cancer or tumors.

[0003] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused the Coronavirus Disease 2019 (COVID-19) pandemic, creating an unprecedented crisis for public health and the global economy. In addition to vaccines, the development of new SARS-CoV-2 treatments to reduce mortality rates, particularly in severe patients, is essential to completely overcome the COVID-19 pandemic.

[0004] Because the process of coronavirus entry into host cells is essential to the virus's infectivity and pathogenicity, this step is considered an important target for therapeutic intervention. During entry into host cells, SARS-CoV-2 binds to the host cell receptor Angiotensin-Converting Enzyme 2 (ACE2), which was first reported as the receptor for SARS-CoV in 2003. The process of SARS-CoV-2 entering cells relies on the interaction between the spike (S) glycoprotein and ACE2, which includes the processes of viral attachment to host cells, endocytosis, and membrane fusion.

[0005] The spike protein of SARS-CoV-2 is cleaved into S1 and S2 subunits by proprotein-converting enzymes, such as furin, in virus-producing cells. Therefore, mature SARS-CoV-2 consists of two non-covalently coupled S subunits; S1 is responsible for ACE2 binding, while S2 serves to anchor the S-protein trimer complex to the cell membrane. In particular, S2 contains a fusion peptide composed of hydrophobic amino acid residues, which is inserted into the target cell membrane to facilitate membrane fusion. Specifically, the S2 subunit contains a cleavage site called the “S′ site,” which is recognized by the transmembrane protease serine 2 (TMPRSS2) on the cell surface. This cleavage induces the formation of a fusion pore, allowing the viral genome to be released directly into the cytoplasm during infection.

[0006] In addition, independently of TMPRSS2, the full-length spike protein can be cleaved into a fusion-capable S2 form by cathepsin L within acidified endosomes following clathrin-mediated endocytosis. Therefore, each step of the viral entry process is highlighted as a potential therapeutic target for blocking SARS-CoV-2 infection.

[0007] Inositol phospholipids play a crucial regulatory role in cellular physiology through interactions mediated by their head groups. They are reversibly phosphorylated by the cooperative action of phosphoinositide (PI) kinases and phosphatases to regulate various biological processes. These processes include, in particular, endocytosis, membrane transport, the cytoskeleton, and autophagy. Among phosphoinositide kinases, PIKfyve, a phosphoinositide kinase containing the FYVE finger, is an important enzyme involved in vesicle transport and is essential to the viral life cycle. This enzyme has garnered attention as a promising therapeutic target for novel viral diseases such as Ebola and Marburg. Notably, PIKfyve has recently been suggested as a therapeutic target for SARS-CoV-2 through studies using specific inhibitors such as afilimod, YM201636, and SGC-PIKFYVE-1.

[0008] In addition, phosphatidylinositol 4-phosphate 5-kinase (including isoforms PIP5K, PIP5K1A, PIP5K1B, and PIP5K1C) generates PtdIns(4,5)P2 in clathrin-coated vesicles, which is essential for the intracellular entry of SARS-CoV-2. However, the effects of targeting PIP5K on SARS-CoV-2 endocytosis and cellular entry are not yet known.

[0009] Meanwhile, genomic instability is a representative characteristic of most cancer cells, and it is increasingly being revealed that defects in DNA repair function induce mutant phenotypes and chromosomal abnormalities, thereby promoting the process of cellular oncogenesis. Homologous recombination (HR) is a high-precision DNA repair pathway that repairs double-strand breaks (DSBs) using homologous DNA sequences. This process is particularly important during the S and G2 phases of the cell cycle, when sister chromatids are present, and is essential for maintaining genomic stability. RAD51, a key recombinant enzyme of HR, enables error-free DSB repair by binding to single-stranded DNA (ssDNA) to form nucleoprotein filaments and facilitating strand invasion into homologous sequences. Due to these critical functions, the expression of RAD51 is strictly regulated at various levels, including transcriptional, post-transcriptional, and post-translational stages. Transcriptional regulation of RAD51 is mediated by various transcription factors that respond to DNA damage and cell cycle progression. For example, the tumor suppressor protein p53 inhibits RAD51 transcription under genotoxic stress conditions, thereby preventing excessive HR from inducing genomic instability. Conversely, E2F1 promotes RAD51 expression during the S and G2 phases, when HR activity increases. While the regulation of RAD51 at the mRNA level is well-studied, how it is regulated at the protein level has not yet been fully elucidated. To date, the E3 ubiquitin ligase RFWD3 has been reported to be involved in the chromatin-based regulation of the single-stranded DNA binding protein RPA and RAD51.

[0010] Cullin 4A (Cul4A) is a scaffold protein of the CRL4 ubiquitin ligase complex that acts in conjunction with Damage-Specific DNA Binding Protein 1 (DDB1) and DDB1-Cul4 Associated Factor (DCAF). Cul4A plays a crucial role in maintaining genomic stability by ubiquitinating and degrading various substrate proteins. Dysfunction of Cul4A is associated with various cancers, leading to increased cell proliferation, genomic instability, and treatment resistance.

[0011] Genomic instability observed in cancer often stems from defects in one or more DNA repair pathways, which provide a selective advantage for cancer cells to evolve into more malignant forms. These defects cause cancer cells to rely more heavily on the remaining DNA repair pathways for survival. A therapeutic strategy that exploits this vulnerability is called synthetic lethality. In situations where a specific DNA repair pathway is already deficient, inhibiting another pathway that compensates for it can induce apoptosis.

[0012] This synthetic lethality strategy has been applied particularly successfully in HR-deficient cancers with BRCA mutations. Mutations in the BRCA1 or BRCA2 genes increase the risk of developing breast and ovarian cancer; indeed, approximately 10% of breast cancers and 15% of ovarian cancers are associated with BRCA mutations. BRCA1 and BRCA2 proteins play crucial roles in HR, DNA replication fork protection, and ssDNA gap inhibition. Mutations in these genes cause cancer cells to rely on alternative pathways, such as PARP1-dependent ssDNA repair, replication fork protection, translesion synthesis, or DSB repair. Against this backdrop, inhibiting PARP1 leads to the accumulation of lethal DNA damage and induces apoptosis in cancer cells with BRCA1 / 2 mutations, while having a relatively less significant impact on normal cells. PARP inhibitors (PARPis), such as olaparib, niraparib, rucaparib, veliparib, and talazoparib, have received U.S. FDA approval, marking a significant advance in the treatment of BRCA-mutated breast and ovarian cancers. These drugs induce apoptosis in HR-deficient cancer cells by trapping PARP1 at ssDNA damage sites. However, despite these therapeutic effects, tumors acquire resistance to PARPi through various mechanisms. This resistance can arise through diverse mechanisms, including the restoration of BRCA function (secondary mutations or re-expression), inactivation of DNA damage sensor proteins such as 53BP1, increased translesion synthesis that bypasses damage sites to continue DNA replication, and increased drug shedding. To date, effective treatments for PARPi-resistant tumors are limited, and new strategies are needed to overcome this challenge.

[0013] ATAD5 (ELG1 in yeast) is an essential protein that removes PCNA during DNA replication. A deficiency in ATAD5 function leads to an excessive retention of PCNA in chromatin, inducing replication fork arrest and increased replication stress, which ultimately results in genomic instability and tumor formation. In particular, the ATAD5-luciferase reporter system is strongly induced under replication stress conditions and has been widely used as an indicator to measure the replication stress response. In a previous study, we reported that a small molecule called ML367 inhibits the increase of ATAD5-luciferase under replication stress conditions.

[0014] In addition, we have been screening compounds that regulate replication stress responses using ATAD5 protein induction as an indicator.

[0015] Previously, we confirmed that a small molecule compound called ML367 could inhibit the DNA replication stress response induced by 5-fluorouridine (5-FUrd). Among the derivatives of ML367, compounds that are structurally similar and exhibit superior DNA replication stress inhibitory activity were identified, and among about 100 derivatives, UNI418 was found to strongly inhibit the growth of PARP inhibitor-resistant tumors.

[0016] In this study, we characterized UNI418, a novel PIP5K1C and PIKfyve dual inhibitor. We demonstrated that UNI418 can inhibit SARS-CoV-2 infection in cell models, suggesting the potential for this class of PIPK inhibitors to be developed as an effective antiviral agent against SARS-CoV-2.

[0017] Furthermore, in this study, ML367 and its derivative UNI418 were identified as inhibitors of replication stress response. It was revealed that they reduce intracellular IP6 levels by inhibiting PIKfyve and PIP5K1C, and induce the degradation of RAD51, CHK1, and CtIP in a Cul4A-dependent manner. Additionally, it was confirmed that WDR5 acts as a DCAF for Cul4A to determine substrate specificity for RAD51 and CHK1. The reduction of these key HR proteins inhibited HR and induced selective apoptosis in PARP1-deficient cells or PARPi-resistant cancer cells. Therefore, we suggest that the HR regulatory pathway mediated by phosphatidylinositol signaling can serve as a novel therapeutic target for BRCA-deficient tumors.

[0018] The present invention provides a 4-aminoquinazoline derivative compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof.

[0019] <Chemical Formula 1>

[0020]

[0021] In addition, the present invention provides an antiviral agent comprising the above compound.

[0022] In one embodiment, the compound may inhibit SARS-CoV-2 infection.

[0023] In one embodiment, the compound may be a dual inhibitor of PIKfyve and PIP5K1C.

[0024] In addition, the present invention provides a pharmaceutical composition for treating cancer or tumors comprising the above compound.

[0025] In one embodiment, the cancer may be a DNA repair-dependent cancer.

[0026] In one embodiment, the tumor may be a BRCA dysfunction tumor or a PARP inhibitor-resistant tumor.

[0027] In one embodiment, the cancer or tumor may be one selected from the group consisting of BRCA-mutated cancer, BRCA-deficient tumor, and PARP1-deficient tumor.

[0028] In one embodiment, the compound may be administered in combination with a PARP inhibitor.

[0029] In one embodiment, the cancer may be breast cancer and ovarian cancer.

[0030] In one embodiment, the tumor may be a colon tumor.

[0031] It has been confirmed that the 4-aminoquinazolin derivative compound of the present invention inhibits the proteolytic activation of cathepsin regulated by PIKfyve, thereby inhibiting an essential step for the virus to escape from the endosome, and inhibits the influx of the virus into the cell by blocking ACE2-mediated endocytosis through PIP5K1C inhibition. In addition, the 4-aminoquinazolin derivative compound of the present invention can be usefully employed in the treatment of PARP inhibitor-resistant tumors by increasing the sensitivity of tumors to PARP inhibitors.

[0032] Fig. 1. UNI418 specifically targets PIP5K1 and PIKfyve. a: Chemical structure of UNI418. The 4-quinazolinamine core structure is indicated in green. b: Kinase profiling analysis table. Inhibition of various kinases was measured at a concentration of 1 μM of UNI418 and analyzed using the SelectScreen Kinase Profiling Service (Thermo Fisher Scientific). c: Cell thermal variation analysis. Exogenously expressed GFP-PIP5K1C and GFP-PIKfyve were heated at the indicated temperatures with and without UNI418 treatment, and the presence of proteins in the lysis fraction was confirmed by Western blot analysis.

[0033] Fig. 2. UNI418 inhibits autophagy. a: Western blot analysis of p62, LC3B-I, LC3B-II, and GAPDH in the presence of UNC3230, afilimod, and UNI418. b: Immunofluorescence staining using LC3B (green) and p62 (red) antibodies after treatment with UNC3230, afilimod, and UNI418, and the image inside the white square box is shown enlarged on the right. Scale bar, 20 μm. c: Quantification of fluorescence intensity regions in the immunofluorescence image (b) after treatment with UNC3230, afilimod, and UNI418. Quantification of autophagy flux with and without UNI418 treatment under normal conditions and starvation conditions induced by HBSS. RPE1 cells were treated with UNI418 (0.5 μM or 1 μM) for 2 hours in the presence or absence of lysosomal inhibitors (bafilomycin A1, BFA). Representative Western blot images (d) and graphs represent the means of four independent experiments (e). Error bars indicate the standard deviation (SD). Statistical analysis was performed using two-way ANOVA, with *p < 0.05 and ***p < 0.001.

[0034] Fig. 3. UNI418 has a negative effect on autophagocytome-lysosome fusion and endosome acidification. a: Live cell image of HEK293T cells stably expressing mCherry-GFP-LC3 at the indicated time after treatment with 0.5 μM UNI418, and the image inside the white square box is shown enlarged on the right. Scale bar, 30 μm. The number (b) and area (c) of GFP-positive spots per cell were quantified using ImageXpress. d: Immunofluorescence image showing inhibition of endo-lysosome acidification by UNI418. Vero cells were treated with mock or 1 μM UNC3230, afilimod, and UNI418 at 37°C for 1 hour. Acridin orange (4 μg / mL) was added to the treated live cells and incubated for an additional 30 minutes. Subsequently, analysis was performed using a confocal microscope with two emission wavelengths of 493–560 nm (green) and 590–720 nm (red) at 488 nm excitation. Merged images are presented, and the image inside the white square box is magnified on the right. Original magnification, x630. The ratio of green to red fluorescence intensity (e) and the area of ​​the fluorescence spot (f) were quantified. (b, c, e, and f) Data are expressed as mean ± SEM and include at least 200 spots. Statistical significance was determined using Student's t-test, with *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. ns, not significant.

[0035] Fig. 4. UNI418 delays cathepsin maturation and SARS-CoV-2 spike cleavage. a Representative Western blot image showing pro- and mature cathepsin D after treatment with indicated concentrations of UNC3230, afilimod, and UNI418. GAPDH was used as a loading control. b, c Evaluation of the co-location of cathepsin D and LAMP1 after treatment with UNC3230, afilimod, and UNI418 in Vero cells for 4 hours. Immunofluorescence staining (b) and Pearson correlation coefficients between LAMP1 and cathepsin D distributions (c) are shown. Scale bar, 15 μm. Individual cell images containing at least 45 cells per sample were randomly cropped and co-locations were analyzed using JACoP in ImageJ. Error bars represent SD. Statistical significance was determined using Student's t-test ***p < 0.001, ns, not significant. d, e The maturation of cathepsin L in Vero cells was analyzed by Western blot. (d) Representative Western blot image showing pro- and mature cathepsin L levels after treatment with the indicated concentrations of UNI418. GAPDH was used as a loading control. (e) The ratio of cathepsin L to pro-cathepsin L was quantified and expressed as mean ± SEM, n=3. Statistical significance was determined using Student's t-test, *p < 0.05, **p < 0.01. f SARS-CoV-2 spike protein cleavage was analyzed with and without UNI418 treatment at specific times. HEK293T cells (293T-ACE2) stably expressing ACE2 were treated with SARS-CoV-2 spike protein (Spike-HexaPro) in the presence or absence of 0.5 μM UNI418, and Western blots were performed for SARS-CoV-2 spike, ACE2, and GAPDH. The g-treated S2 / GAPDH ratio was quantified and expressed as mean ± SEM, with n=4.Statistical analysis was performed using Two-way ANOVA, and *p < 0.05.

[0036] Fig. 5. UNI418 inhibits SARS-CoV-2 infection. a. Antiviral activity and cytotoxicity of UNI418. Vero cells were mock-infected or infected with SARS-CoV-2 at MOI 0.01 or 0.001, and then individually treated with increasing concentrations of UNI418, while afilimod, UNC3230, and remdesivir were used as controls. The number of virus spike protein-positive cells was counted using immunofluorescence microscopy with anti-spike antibodies on day 2 (UNI418, afilimod, and remdesivir) or day 1 (UNC3230) after infection. Antiviral activity (EC50) was calculated as the concentration that reduces the number of spike-positive cells by 50% (red line). Simultaneously, cytotoxicity (CC50) was defined as the concentration that reduces the viability of mock-infected cells by 50% using MTT (black line). The selectivity index (SI) refers to the ratio of CC50 to EC50. Values ​​are expressed as the mean ± SEM from three independent experiments. b. Reduction of SARS-CoV-2 genomic RNA via quantitative RT-PCR. Vero cells were infected with SARS-CoV-2 (MOI 0.001) at 37°C for 1 hour, followed by removal of non-adherent viruses and treatment with UNI418 or afilimod at increasing concentrations for 24 hours. Viral RNA was purified from the culture supernatant, and one-step quantitative RT-PCR was performed to measure the relative amount of viral NP genes. Values ​​are expressed as the mean ± SEM of the three samples. Statistical significance was evaluated by two-way ANOVA including Dunnett's test of multiple comparisons. *p < 0.05; ***p < 0.001; ****p < 0.0001. c. Reduction of SARS-CoV-2 NP expression by UNI418. Vero cells infected with SARS-CoV-2 were treated with UNI418 or remdesivir (RDV) at increasing concentrations.Cell lysates were harvested on day 1 post-infection, and the expression of viral nucleocapsid protein (NP) was analyzed by Western blot. β-actin was used as a loading control. Marker sizes are indicated on the left side of the gel. d Blockade of the endocytosis pathway by UNI418 in SARS-CoV-2 infected cells. Vero cells were pretreated with DMSO (mock, top), 1 μM UNI418 (middle), or 1 μM afilimod (bottom) for 1 hour at 37°C. To synchronize viral infection, high-purity purified SARS-CoV-2 (MOI 10) was infected in the presence of each compound at 4°C for 1 hour. Afterward, the temperature was returned to 37°C, and cells were fixed at 1, 2, 4, and 8 hours post-infection and immunostained with antibodies specific to viral NP (green) and cellular EEA1 (red). In all samples, nuclei were counterstained with DAPI (blue). Original magnification, x630.

[0037] Figure 6. UNI418 inhibits ACE2 receptor-mediated viral influx. a. ACE2 downregulation induced by SARS-CoV-2 infection was evaluated in Vero cells. Cells were infected with SARS-CoV-2 at the indicated concentrations of UNI418, and Western blot analysis was performed on ACE2, cleaved ectodomain (ACE2ecto), and GAPDH at 1 and 3 hours post-infection. b. ACE2 endocytosis induced by the interaction between ACE2 and the spike RBD protein (Spike-RBD) was analyzed using UNC3230, Afilimod, UNI418, and Dinosaur. HEK293T cells were transfected with hACE2-GFP and treated with 0.5 μM of each compound; live cell imaging was performed at specified times to observe the distribution of hACE2-GFP. Membrane-bound ACE2 and internalized ACE2 were indicated by yellow and white arrows, respectively. Scale bar, 10 μm. c The area ratio of internalized hACE2-GFP and membranous hACE2-GFP in individual cells was quantified and expressed as mean ± SEM, n>=20. Statistical significance was evaluated by one-way ANOVA, ***p < 0.001, ns, not significant.

[0038] Fig. 7. PIP5K1C and PIKfyve are key regulators of SARS-CoV-2 S protein-mediated viral influx. a Analysis of pseudotype virus influx at indicated concentrations of UNI418. Pseudotype virus particles containing luciferase reporters were generated using VSV-G and SARS-CoV-2 spike (Wuhan-Hu-1, Delta (B.1.617.2), Omicron (BA.1)) expression plasmids. 293T-ACE2 cells were infected in the presence of each concentration of UNI418, and luciferase activity was measured 24 hours after infection to express relative influx efficiency as mean ± SEM (n=3). Statistical significance was evaluated by two-way ANOVA, ***p < 0.001. b, c Analysis of Wuhan-Hu-1 spike-pseudotype virus influx after PIKfyve and PIP5K1C depletion. HEK293T-ACE2 cells were transfected with siRNA, and luciferase-based influx analysis (top) and Western blot analysis (bottom) were performed. Data were expressed as mean ± SEM (n=3), and statistical analysis was performed using Student's t-test (*p < 0.05, **p < 0.01). d Wuhan-Hu-1 spike-pseudotype virus influx in 293T-ACE2 cells after treatment with afilimod or UNC3230 alone and in combination was measured by luciferase activity. Data were expressed as mean ± SD (n=3), and statistical analysis was performed using Student's t-test (*p < 0.05, **p < 0.01, ***p < 0.001). e, f Synergistic effect of UNC3230 and afilimod in SARS-CoV-2 infection. Vero cells infected with an MOI of 0.01 were treated with UNC3230 and afilimod diluted three-fold at various ratios. e The antiviral efficacy of UNC3230 (red) and afilimod (blue) was measured individually for each combination 1 day after infection. f Isobologram graph showing the sum of fractional EC50 values ​​(ΣFEC50) for each combination.The average value at ratios of 4:1, 3:2, 2:3, and 1:4 was 0.68. A schematic model illustrating the mechanism by which UNI418 inhibits the influx of SARS-CoV-2 into cells by targeting g PIP5K1C and PIKfyve.

[0039] Fig. 8. UNI418 induces vacuole formation in RPE1 cells. a Image of RPE1 cells with or without UNI418 treatment. b Graph analyzing vacuole formation in RPE1 cells at various concentrations. Data are presented as mean ± SEM (n=4).

[0040] Fig. 9. UNI418 inhibits PIP5K1B / C and PIKfyve. a Graph of PIP5K1 kinase inhibition according to 10-step concentration titration of UNI418. The IC50 values ​​of PIP5K1 kinase were analyzed using Thermo Fisher Scientific's SelectScreen kinase profiling service. b The Kd(nM) values ​​for the inhibition of PIP5K1C and PIKfyve were measured using the Eurofins kinase analysis service.

[0041] Fig. 10. UNI418 reduces the amount of PIP2 in RPE1 cells. a. PtdIns(4,5)P2 levels in RPE1 cells with and without UNI418 treatment. PtdIns(4,5)P2 levels were measured by flow cytometry. Data are presented as mean ± SEM (n=7). Statistical significance was analyzed using Student's t-test, **p < 0.01. b. Representative flow cytometry graph showing PIP2 levels after treatment with various concentrations of UNI418.

[0042] Fig. 11. PIKfyve is the cause of vacuolar formation induced by UNI418 treatment. a Immunofluorescence stained image showing EEA1 (green, yellow arrowhead) and LAMP1 (red, white arrowhead) in RPE1 cells treated with UNC3230, afilimod, and UNI418; the image within the white square box is shown enlarged on the right. Scale bar, 15 μm. b, c Quantified EEA1(b) and LAMP1(c) positive vacuolar perimeters under each drug treatment condition. Data are presented as mean ± SEM (n > 20). Statistical significance was analyzed using Student's t-test, ***p < 0.001.

[0043] Fig. 12. Vacuole formation induced by PIKfyve inhibition is reversible. a Representative images at each time point after treatment or removal of UNC3230, afilimod, and UNI418 in RPE1 cells. Scale bar, 50 μm. b Zoomed-in image of a specific area of ​​the top image.

[0044] Fig. 13. Western blot results for autophagy flow analysis of Fig. 2e.

[0045] Fig. 14. Inhibition of endo-lysosomal acidification by PIP5K1C siRNA and increase in vacuole size by PIKfyve siRNA. a Vero cells were treated with control siRNA (si-control), PIP5K1C siRNA (siPIP5K1C), PIKfyve siRNA (siPIKfyve), or a combination of siPIP5K1C and siPIKfyve (50 nM each). Two days after transfection, acridin orange (4 μg / mL) was applied for 30 minutes. Subsequently, fluorescence images were captured using a confocal microscope at wavelengths of 493–560 nm (green) and 590–720 nm (red) after excitation at 488 nm. Merged images are presented, and the region of interest (ROI) indicated by the white box is shown magnified on the right. Original magnification ×630. b. The ratio of red to green fluorescence intensity and c. the area of ​​the fluorescent spot were quantified. Data are presented as mean ± SEM (n > 30). d, e. Graphs confirming the expression of PIP5K1C (d) and PIKfyve (e) using real-time PCR. Data are presented as mean ± SEM (n=3). (b, c, d, e) Statistical significance was analyzed using Student's t-test, where *p < 0.05, **p < 0.01, ****p < 0.0001, and ns indicate insignificance.

[0046] Fig. 15. Confirmation of deacidified vesicles by UNI418. a Vero cells were either mocked or transfected with plasmids expressing mCherry-fused Rab5 (mCherry-Rab5), Rab7 (mCherry-Rab7), and LAMP1 (mCherry-LAMP1). Two days after transfection, the cells were treated with 1 μM UNI418 for 1 hour and then stained with acridine orange (AO) for 30 minutes. AO-derived fluorescence was detected using bandpass filters at 490-555 nm (green) and 615-720 nm (red) after 488 nm excitation. In the same samples, early endosome (Rab5), late endosome (Rab7), and lysosome (LAMP1) labeling was visualized at 587-600 nm after 555 nm excitation. Deoxygenated vesicles are indicated by white arrows in the overlay image. The region of interest (ROI) marked by a white box is presented magnified on the right. b Graph showing the green / red (G / R) ratio at mCherry positive spots. Statistical significance was analyzed using an unpaired t-test, and ****p < 0.0001.

[0047] Fig. 16. UNI418 is not merely a lysosomotropic drug. a Western blot results of LAMP1 under UNI418 and chloroquine treatment conditions. GAPDH was used as a loading control. NT means no treatment. b Immunofluorescence images showing LAMP1 accumulation in RPE1 cells after treatment with indicated concentrations of chloroquine and UNI418; the image within the white square box is magnified and displayed on the right. Scale bar, 20 μm. c Mean fluorescence intensity in individual cells was quantified. Data are presented as mean ± SEM (n > 20). Statistical significance was analyzed using Student's t-test, ***p < 0.001.

[0048] Fig. 17. UNI418 inhibits the proteolytic maturation of cathepsin. a, b. Western blot analysis and quantitative results via band intensity measurement of CTSD and its precursor (Pro-CTSD) showing the inhibition of cathepsin D maturation by UNI418 in RPE1 cells. c, d. Western blot analysis and quantitative results via band intensity measurement of CTSD and Pro-CTSD showing the inhibition of cathepsin D maturation by UNI418 in HCT116 cells. a, c. GAPDH was used as a loading control. b, d. The CTSD / Pro-CTSD ratio is presented as mean ± SEM (n=4). Statistical significance was analyzed using Student's t-test, *p < 0.05, **p < 0.01, ***p < 0.001. e. Western blot results showing changes in cathepsin D at each time point under UNI418 treatment or release conditions.

[0049] Fig. 18. Western blot analysis of cathepsin L maturation in Fig. 4e.

[0050] Fig. 19. Schematic of the experimental workflow for the antiviral analysis and cytotoxicity test of Fig. 5a.

[0051] Fig. 20. Immunofluorescence staining showing viral NP (green) and cellular EEA1 (red) in SARS-CoV-2 infected Vero cells. ad Enlarged view of individual and merged images extracted from Fig. 5d. e Manders' colocalization coefficient of EEA1 and NP. Statistical significance was analyzed using an unpaired t-test, and ****p < 0.0001.

[0052] Fig. 21. Analysis of SARS-CoV-2 spike-like virus (pseudotyped virus) influx. a Cell influx of Wuhan-Hu-1 spike-like virus was measured after depleting PIP5K1B in 293T-ACE2 cells. After transgenerating HEK293T-ACE2 cells with the corresponding siRNA, luciferase-based influx analysis (top panel) and Western blot (bottom panel) were performed. b Pseudotyped virus influx analysis was performed after depleting PIP5K1A in 293T-ACE2 cells, and PIP5K1A expression was confirmed through luciferase-based influx analysis (right panel) and real-time PCR (left panel). c, d Concentration-dependent influx analysis of afilimod (c) and UNC3230 (d). Data are presented as mean ± SD (n=3). Statistical significance was analyzed using Student's t-test, where *p < 0.05, ***p < 0.001, and ns indicate insignificance.

[0053] Fig. 22. Identification of compound UNI418 that inhibits DNA damage response signals

[0054] This outlines a high-throughput screening to identify compounds that inhibit the aDNA damage response.

[0055] Chemical structures of bML367 and UNI418. Structures commonly shared by the two compounds are shown in green.

[0056] Luciferase-ATAD5 assay to measure cDNA damage response. HEK293T cells expressing luciferase-ATAD5 were treated with ML367 or UNI418 in the presence of indicated concentrations of 5-FUrd for 24 hours, followed by a luciferase assay. Luciferase activity was normalized by setting the untreated group (NT) to 1. Mean ± SEM (UNI418 n = 2, ML367 n = 6, independent replicates). One-way ANOVA, ***p = 0.001.

[0057] d,e Western blot showing pRPA32-S4 / 8, total RPA32, pCHK1, and CHK1 levels after treatment with ML367 or UNI418 in the presence of replication stress inducers (camptothecin (CPT) or hydroxyurea (HU)). Cells were treated with ML367 for 24 hours, UNI418 for 18 hours, ATR inhibitor (ATRi) for 18 hours, HU for 4 hours, or CPT for 3 hours prior to harvest. Numbers above the bands indicate relative signal intensity normalized to the indicated loading controls. Representative results from three independent experiments are presented.

[0058] Fig. 23. UNI418 inhibits PIP5K1C and PIKfyve and reduces IP3, IP4, IP5, and IP6.

[0059] Results of the kinase profiling assay performed using DiscoverX after aUNI418 treatment.

[0060] The inhibition of various kinases at 1 μM UNI418 was measured using the bThermo Fisher Scientific Solutions SelectScreen kinase profiling service. KD (nM) values ​​for PIKfyve and PIP5K1C inhibition were determined using the SelectScreen kinase assay. Representative results obtained from two independent experiments are presented.

[0061] The kinase domains of cMBP-tagged PIP5K1C and PIKfyve were immobilized on a CM5 chip. SPR analysis was performed after injecting UNI418. The black curve represents the model prediction curve corresponding to the color-coded experimental sensogram. Representative results obtained from three independent experiments are presented.

[0062] The interactions between dUNI418 and PIP5K1C or PIKfyve were evaluated by CESTA analysis. Cell lysates treated with DMSO or UNI418 were heated to the indicated temperatures. The interactions between UNI418 and PIKfyve and PIP5K1C were assessed by measuring the amount of protein remaining in the soluble fraction via Western blot analysis. Numbers above the bands represent the relative signal intensity normalized to the indicated loading controls. Representative results obtained from three independent experiments are presented.

[0063] Schematic diagram of phosphoinositide and inositol phosphate metabolism mediated by ePIKfyve and PIP5K1C.

[0064] Various amounts of IP were measured using an IP profiling assay after treatment with fDMSO or UNI418. Mean ± SEM (n = 3, independent replicates). Two-sided Student's t-test, *p = 0.05, **p = 0.01.

[0065] Fig. 24. UNI418 selectively inhibits the HR pathway by reducing RAD51, CHK1, and CtIP protein levels.

[0066] Protein levels in aHCT116 cells under conditions of UNI418 treatment for 18 hours and HU treatment for 4 hours or no treatment. Representative results obtained from three independent experiments are presented.

[0067] bRPE1 cells were treated with DMSO or UNI418 for 18 hours, exposed to IR, and subjected to EdU pulse labeling. Foci were quantified in EdU-positive nuclei at 1, 3, and 6 hours after IR treatment. Representative images are presented along with foci quantification. Mean ± SEM (n = 54 nuclei). Two-way ANOVA, ***p = 0.001.

[0068] Western blot analysis of the indicated proteins in cells treated with cUNI418 for 18 hours and MG132 for 3 hours or not treated. Representative results obtained from three independent experiments are presented.

[0069] Degradation kinetics of RAD51 and CHK1 after cycloheximide treatment in dUNI418-treated cells. Representative blots are presented along with quantified results relative to HSP90. Mean ± SEM (RAD51 n = 3, CHK1 n = 2, independent replicates). Two-way ANOVA, **p = 0.01, ***p = 0.001.

[0070] HR and NHEJ efficiency were measured using the GFP reporter assay after 16 hours of eUNI418 treatment. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05, ***p = 0.001.

[0071] HCT116 WT and PARP1 measured by CellTiter-Glo assay after 72 hours of fUNI418 treatment - / - Cell viability. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, ***p = 0.001.

[0072] HCT116 WT and PARP1 after treatment with 0.5 μM g UNI418 for 24 hours - / -Analysis of apoptosis in cells. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, **p = 0.01, ***p = 0.001.

[0073] HCT116 cell viability at 72 hours after olaparib treatment with or without hUNI418. Mean ± SEM (olaparib n = 6, UNI418+olaparib n = 4). Two-way ANOVA, ***p = 0.001.

[0074] Analysis of apoptosis in HCT116 cells after 5 days of treatment with 0.2 μM UNI418 or 10 μM olaparib. Mean ± SEM (n = 3). One-way ANOVA, *p = 0.05, **p = 0.01. Numbers above the band represent relative signals normalized to the loading control.

[0075] Fig. 25. PIKfyve and PIP5K1C inhibit the HR pathway by reducing RAD51, CHK1, and CtIP protein levels.

[0076] Western blot analysis for PIP5K1B, PIP5K1C, CHK1, RAD51, and GAPDH was performed after treating aRPE1 cells with labeled siRNA. Representative results obtained from three independent experiments are presented.

[0077] The indicated protein levels were analyzed by Western blot in bRPE1 cells treated with a control or siRNA and UNI418 for 18 hours or without treatment. Representative results obtained from three independent experiments are presented.

[0078] HR frequencies were measured by performing a GFP reporter assay after transfecting cDR-GFP U2OS cells with siRNA against PIP5K1B, PIP5K1C, or PIKfyve. RAD51 depletion was used as a positive control. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, ***p = 0.001.

[0079] RPE1 cells transfected with the siRNAs labeled d and e were treated with the labeled concentrations of olaparib or UNI418 for 72 hours, after which a CellTiter-Glo assay was performed. Mean ± SEM (olaparib n = 13, UNI418 n = 14, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001. Numbers above the bands represent relative signal intensity normalized to the labeled loading controls.

[0080] Fig. 26. UNI418 reduces IP6 levels and induces HR protein degradation through the nedylation of Cul4A.

[0081] Western blot analysis was performed on nedylated Cul4A and HR protein levels under conditions of UNI418 treatment for 18 hours followed by 10 minutes of IP6 treatment or no treatment (a), or transfection with siPIP5K1C, siPIKfyve, or both simultaneously (b). The lysis buffer contained 1 mM N-ethylmaleimide. Representative Western blot images are shown at the top, and the relative band intensity of normal Cul4A versus nedylated Cul4A is shown at the bottom. Mean ± SEM (n = 3, independent replicates). One-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0082] HR protein levels were analyzed by Western blot under conditions where cCul4A siRNA was treated and UNI418 was treated for 18 hours or not treated. Representative results obtained from three independent experiments are presented.

[0083] The number of RAD51 foci was measured by immunofluorescence in RPE1 cells treated with 0.5 μM UNI418 for 18 hours and either treated with 2 mM IP6 or not treated. Mean ± SEM (NT, n = 173, UNI418, n = 253, IP6, n = 102, UNI418 + IP6, n = 105 nuclei). One-way ANOVA, **p = 0.01, ***p = 0.001.

[0084] HR frequency was measured in eDR-GFP U2OS cells after treatment with UNI418 and increasing concentrations of IP6. Mean ± SEM (n = 4, independent replicates). Two-way ANOVA, *p = 0.05, ***p = 0.001. Numbers above the bands represent the relative signal normalized to the loading control.

[0085] Fig. 27. WDR5 mediates the degradation of RAD51 as the DCAF of the Cul4A complex.

[0086] HR protein levels were analyzed by Western blot after treatment with aCul4A and WDR5 siRNA alone or in combination. Representative results from three independent experiments are presented.

[0087] The interactions between WDR5 and its binding partners were analyzed via co-immunoprecipitation under bMG132 treatment conditions. FLAG-tagged WDR5 was transiently expressed in HCT116 cells, followed by immunoprecipitation with an anti-FLAG antibody. Co-precipitated proteins, including Cul4A, RAD51, CHK1, and DDB1, were identified by Western blot. Representative results from three independent experiments are presented.

[0088] Cell viability was evaluated by the CellTiter-Glo assay after 72 hours of treatment with olaparib in cells depleted of cCul4A, WDR5, or both proteins simultaneously. Mean ± SEM (n = 4, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0089] HR protein levels were analyzed by Western blot with and without 2 Gy IR treatment of dCul4A and RFWD3 siRNA, either alone or in combination. Representative results from three independent experiments are presented. Numbers above the bands represent the relative signal normalized to the loading control.

[0090] Fig. 28. UNI418 selectively kills PARP1-deficient tumors and BRCA revertant cancer cells.

[0091] aHCT116 WT or PARP1 - / - After xenografting cells into mice, they were treated with vehicle or UNI418, and tumor volume was measured. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05.

[0092] Tumor volumes were measured after treating bHCT116 xenograft mice with vehicle, UNI418, olaparib, or UNI418 + olaparib. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, **p = 0.01.

[0093] Relative cell viability was measured by CellTiter-Glo assay after treating c-ePEO-1 and C4-2 cells with (c) olaparib, (d) UNI418, or (e) 0.25 μM UNI418 and increasing concentrations of olaparib for 72 hours. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0094] Cell viability was measured after treating f-hCapan-1 and C2-2 cells with (f) olaparib, (g) UNI418, or (h) 0.25 μM UNI418 and increasing concentrations of olaparib for 72 hours. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001. IC50 values ​​for the ch panel are presented in Figure 41.

[0095] iPEO-1 and C4-2 cells were treated with 0.2 μM UNI418 and 10 μM olaparib for 5 days, followed by Annexin V / propidium iodide staining and FACS analysis. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, **p = 0.01, ***p = 0.001.

[0096] A hypothetical model of the mechanism of action of UNI418 in jHR defects was diagrammed. Lipid kinases such as PIKfyve and PIP5K1C regulate intracellular IP6 levels through the phosphatidylinositol signaling pathway. IP6 inhibits Cul4A ubiquitin ligase and stabilizes key HR proteins such as RAD51 and CHK1 by promoting the denedylation (N8) of Cul4A by the COP9 signalosome (CSN). When UNI418 inhibits PIKfyve and PIP5K1C, IP6 levels decrease, and Cul4A is activated through denedylation. As a result, WDR5 acts as a substrate-recognizing DCAF, inducing the degradation of HR proteins.

[0097] Fig. 29. Inhibition of ATAD5-luciferase expression and CHK1 activity by ML367 and UNI418

[0098] Luc-ATAD5 expression was analyzed by Western blot after treatment with ML367 or UNI418 with a5-FUrd for 16 hours. Representative results from three independent experiments are presented.

[0099] Changes in CHK1 and phosphorylated CHK1 induced by UNI418 under conditions with and without b5-FUrd treatment were analyzed by Western blot. Representative results obtained from three independent experiments are presented. Cells were treated with ML367 for 24 hours, UNI418 for 18 hours, ATR inhibitor (ATRi) for 18 hours, or 5-FUrd for 16 hours prior to harvest. Numbers above the bands represent relative signal intensity normalized to the indicated loading controls.

[0100] Fig. 30. Kinase profiling and siRNA validation of candidate kinase targets

[0101] Kinase profiling analysis for CSF1R, DDR1, FLT3, JAK1, KIT, MEK5, MINK1, TRDA, and PDGFRB was performed using aThermo Fisher Scientific SelectScreen 10-point titration.

[0102] Protein levels of CHK1 and RAD51 were analyzed by Western blot after inhibiting the expression of the b-labeled kinases with siRNA. Representative results from three independent experiments are presented. Numbers above the bands represent the relative signals normalized to the loading control.

[0103] Fig. 31. Validation of SPR assay using purified PIKfyve and PIP5K1C proteins

[0104] aMBP-tagged PIKfyve and PIP5K1C proteins were separated by SDS-PAGE, and the purity and integrity of the proteins were confirmed by Coomassie Brilliant Blue staining. Representative results obtained from three independent experiments are presented.

[0105] b. MBP was immobilized on a CM5 chip as a negative control. Changes in the plasmon resonance angle were measured after injecting UNI418. Representative results obtained from three independent experiments are presented.

[0106] Fig. 32. Analysis of phosphoinositide and inositol phosphate levels after UNI418 treatment

[0107] The ratios of PIP, PIP2, and PIP3 levels were measured in aHCT116 cells after 18 hours of treatment with DMSO, UNI418, and afilimod. Mean ± SEM (n = 2, independent replicates). Two-sided Student's t-test, *p = 0.05, **p = 0.01.

[0108] IP3, IP4, IP5, and IP6 levels were measured after treatment with bUNC3230 and afilimod. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0109] c Inositol phosphate was concentrated using titanium dioxide beads in untreated cells (NT) and cells treated with 0.5 μM UNI418 for 18 hours, and then analyzed by HPLC. Empty refers to the baseline control, and IP6 represents the standard IP6 chromatogram.

[0110] Fig. 33. PIKfyve and PIP5K1C combined prediction and CETSA verification of UNI418

[0111] Potential binding structures between UNI418, PIKfyve, and PIP5K1C were predicted using aAutoDock and RosettaDock. The relative positions within the kinase domain were visualized by modeling with ATP.

[0112] CETSA analysis of various PIKfyve mutant proteins in the presence of bUNI418. MBP was used as a loading control.

[0113] CETSA analysis of various PIP5K1C mutant proteins in the presence of cUNI418. MBP was used as a loading control. Representative results from three independent experiments are presented. Numbers above the bands represent the relative signal normalized to the loading control.

[0114] Fig. 34. UNI418 alters HR protein levels and chromatin recruitment without affecting transcription.

[0115] Various DNA repair proteins were analyzed by Western blot after treatment with 0.5 μM UNI418 for 18 hours. Representative results obtained from three independent experiments are presented.

[0116] Cells treated with or untreated with b0.5 μM UNI418 for 18 hours were exposed to IR, and RAD51 foci intensity was quantified at 1, 3, and 6 hours after IR. Analysis was performed on EdU-positive nuclei. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05.

[0117] CtIP and γH2AX foci were analyzed by immunohistochemistry after treatment with cDMSO or UNI418 for 18 hours, with and without IR treatment. Quantification results for CtIP foci are presented on the right. Mean ± SEM (n = 100, 125, 93, 157, 105, 127 nuclei, respectively). One-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0118] Soluble and chromatin-binding fractions were separated from RPE1 cells after 18 hours of dUNI418 or 4 hours of HU treatment and analyzed by Western blot. Representative results obtained from three independent experiments are presented.

[0119] RAD51, CHK1, and CtIP mRNA expression was analyzed by RT-qPCR after 18 hours of eUNI418 treatment. Mean ± SEM (n = 3, independent replicates). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001. Numbers above the bands represent the relative signal normalized to the loading control.

[0120] Fig. 35. UNI418 does not affect the transcriptional regulation of the HR gene.

[0121] Nuclear and cytoplasmic mRNA expression of RAD51, CHK1, and CtIP was measured by RT-qPCR in cell fractions after treatment with 0.5 μM UNI418 in aRPE1 cells for 18 hours. Fraction confirmation results by Western blot are presented on the left. Mean ± SEM (n = 3). Two-way ANOVA, *p = 0.05.

[0122] RNA-FISH analysis was performed on bMock and UNI418-treated cells after 18 hours.

[0123] RAD51 protein levels in control cells, UNI418-treated cells, or siRAD51-treated cells were analyzed by Western blot using a cHR reporter assay. Representative results from three independent experiments are presented.

[0124] dHCT116 WT and PARP1 - / - PARP1 protein levels in cells were analyzed by Western blot. Representative results from three independent experiments are presented. Numbers above the bands represent the relative signal normalized to the loading control.

[0125] Fig. 36. UNI418 increases PARP inhibitor sensitivity and induces synthetic lethality.

[0126] aHCT116 WT and PARP1 - / -After treating cells with various concentrations of UNI418 for 18 hours, levels of CtIP, CHK1, RAD51, and γH2AX were analyzed by Western blot. Representative results from three independent experiments are presented.

[0127] A clonal survival assay was performed for 10 days after treatment with 0.2 μM UNI418, 10 μM olaparib, or combination therapy. Mean ± SEM (n = 9). Two-sided Student's t-test, *p = 0.05, **p = 0.01, ***p = 0.001.

[0128] c CompuSyn-based synergy index for 26g.

[0129] Clonal survival assay for olaparib after dsiRNA treatment. Cells were treated with siRNA followed by olaparib and cultured for 7 days to induce colony formation. Colonies were fixed, stained, and quantified. Mean ± SEM (n = 3). Numbers above the bands represent relative signals normalized to the loading control.

[0130] Fig. 37. IP6 signaling regulates HR protein degradation and PARP inhibitor sensitivity.

[0131] Cul4A nedylation was analyzed by Western blot after the addition of IP6 to cytoplasmic and nuclear extracts. The graph on the right shows the relative band intensity of normal Cul4A versus nedylated Cul4A. Mean ± SEM (n = 3). One-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0132] HR protein expression was analyzed after treatment with bUNI418 for 18 hours and treatment with increasing concentrations of IP6 for 10 minutes. Representative results obtained from three independent experiments are presented.

[0133] HCT116 WT and PARP1 under cUNI418 and IP6 processing conditions - / -Cell viability was measured at 72 hours using the CellTiter-Glo assay. Mean ± SEM (n = 3). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0134] Changes in HR protein expression following dIPPK depletion were analyzed by Western blot under conditions with and without UNI418 treatment. Representative results obtained from three independent experiments are presented.

[0135] Olaparib sensitivity after eIPPK depletion was measured by the CellTiter-Glo assay. Mean ± SEM (n = 3). Two-way ANOVA, *p = 0.05, **p = 0.01, ***p = 0.001.

[0136] IPPK mRNA expression after IPPK depletion using fsiRNA was analyzed by RT-qPCR. Mean ± SEM (n = 3).

[0137] RFWD3 mRNA expression after RFWD3 depletion using gsiRNA was analyzed by RT-qPCR. Mean ± SEM (n = 3). Numbers above the bands represent the relative signal normalized to the loading control.

[0138] Fig. 38. Mouse body weight and pharmacokinetic characteristics of UNI418

[0139] a. Changes in mouse body weight in Fig. 28a, b. Ola refers to olaparib. Mean ± SEM (n = 3). Two-way ANOVA.

[0140] b Pharmacokinetic data of UNI418 in mice. NA means not applicable, IV means intravenous injection, and PO means oral administration.

[0141] Fig. 39. CompuSyn-based synergy effect index corresponding to Figs. 28c-h

[0142] Fig. 40. Abbreviations and full names used in this study.

[0143] FIG. 41. IC50 values ​​of FIG. 24f-h and FIG. 28c-h.

[0144] Fig. 42. SiRNA sequence used.

[0145] The present invention will be explained in more detail below through examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the present invention and do not limit the scope of the present invention.

[0146]

[0147] Study 1: Dual inhibitors of PIP5K1C and PIKfyve inhibit the intracellular uptake of SARS-CoV-2.

[0148] abstract

[0149] The SARS-CoV-2 pandemic has caused unprecedented impacts on global public health and the economy. While vaccines and antivirals have provided effective protection and treatment, the development of new small molecule-based antiviral candidates is essential to improve clinical outcomes against SARS-CoV-2. In this study, we identified UNI418, a dual inhibitor that simultaneously inhibits PIKfyve and PIP5K1C, as a novel chemical agent that inhibits the process of SARS-CoV-2 entering host cells. UNI418 inhibits the proteolytic activation of cathepsin regulated by PIKfyve, thereby suppressing the cathepsin L-dependent proteolytic process in which the SARS-CoV-2 spike protein is cleaved into a mature form. This process is an essential step for the virus to escape from endosomes. Furthermore, we demonstrated that UNI418 inhibits viral entry into cells by blocking ACE2-mediated endocytosis through the inhibition of PIP5K1C. These results define PIKfyve and PIP5K1C as potential antiviral targets and suggest that UNI418 could be a therapeutic candidate for SARS-CoV-2.

[0150]

[0151] Experimental method

[0152] Synthesis of compound UNI418

[0153] N-(5-phenyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-4-quinazolinamine

[0154]

[0155] 4-chloro-2-(4-pyridyl)-quinazoline (0.83 mmol, 200 mg) and 3-amino-5-phenyl-1H-pyrazole (0.87 mmol, 139 mg) were dissolved in DMF. The reaction was stirred at 80 °C for 12 hours. After removing the solvent, the mixture was washed with EtOAc (100 mL × 3) and brine (200 mL × 3). The organic layer was dried, dissolved in EtOH (20 mL), and heated under reflux conditions. After 15 minutes, the solution was cooled and left overnight. Subsequently, the solid was filtered to obtain 200 mg (66%) of brown powder. This powder was decolorized with activated carbon (100 mg) and filtered to obtain 200 mg (66%) of yellow powder. 1 H NMR (400 MHz, DMSO-d6) δ13.12 (s, 1H), 10.70 (s, 1H), 8.79 (dd, J = 4.5, 1.6 Hz, 2H), 8.74 (d, J = 8.2 Hz, 1H), 8.35 (d, J = 5.7 Hz, 2H), 7.99 - 7.89 (m, 2H), 7.83 (t, J = 10.8 Hz, 2H), 7.64 (dd, J = 15.9, 9.7 Hz, 1H), 7.55 (dd, J = 16.1, 8.6 Hz, 2H), 7.46 - 7.33 (m, 2H). 13 C NMR

[0156]

[0157] cell

[0158] Vero81 (ATCC; CCL-81), Vero E6 (ATCC; CRL-1586), HCT116 (ATCC; CCL-247), and HEK293T (ATCC, CRL-11268) cells were maintained in DMEM containing 10% fetal bovine serum (Life Technologies), 100 U / mL penicillin G (Life Technologies), and 100 μg / mL streptomycin (Life Technologies). RPE1 cells were cultured in DMEM / F12 containing 10% fetal bovine serum, 100 U / mL penicillin G, and 100 μg / mL streptomycin. The HEK293T-hACE2 stable cell line was provided by Professor HR Lee (Korea University), and the mCherry-GFP-LC3 HCT116 stable cell line was constructed.

[0159]

[0160] compound

[0161] The following compounds were purchased from the indicated companies: Bafilomycin A1 (Cayman chemical company, 11038), Dynasore (Sigma-Aldrich, D7639), Hoechst (Cayman chemical company, 15547), Remdesivir (MedChem Express, HY-104077), and Afilimod (MedChem Express, HY-14644). In particular, the purity of Remdesivir and Afilimod, which were used as antiviral controls, was certified to be 95% or higher.

[0162]

[0163] Cellular Thermal Shift Assay (CETSA)

[0164] Compound-treated cells were heated to 56°C for 3 minutes to denature and precipitate non-target proteins. The heated cells were immediately froze overnight in liquid nitrogen. After repeating the freezing and thawing cycles twice, the tubes were briefly vortexed. The resulting cell lysate was used for SDS-PAGE.

[0165]

[0166] antibodies

[0167] The following antibodies were used for Western blotting and immunofluorescence analysis; Rabbit polyclonal LC3B (Cell Signaling Technology, 2775S), LC3B (Sigma-Aldrich, L7543), SQSTM1 / p62 (Santa Cruz Biotechnology, sc-25575), PIP5K1C (Cell Signaling Technology, #3296), EEA1 (Santa Cruz Biotechnology, sc-33585), LAMP1 (Cell Signaling Technology, #9091), mouse monoclonal SARS-CoV / SARS-CoV-2 (COVID-19) spike (GenTex, GTX632604), SARS-CoV / SARS-CoV-2 nucleocapsid (Sinobiological, 40143-MM05), PIP5K1B (Santa Cruz Biotechnology, sc-514169), PIKfyve (EMD Millipore, MABS522), ACE2 (R&D systems, MAB933), GAPDH (Santa Cruz Biotechnology, sc-32233), cathepsin D (Santa Cruz Biotechnology, sc-377124), cathepsin L (eBioscience, BMS1032), EEA1 (Cell Signaling Technology, #48353), PIP2(Santa Cruz Biotechnology, sc-53412).

[0168]

[0169] Plasmid structure

[0170] The plasmid expressing SARS-CoV2 HexaPro was provided by Ho Min Kim (Institute for Basic Science). The SARS-CoV-2 spike protein (pcDNA3.1-SARS2-spike) was provided by Fang Li (Addgene plasmid #145032). pBOBI-FLuc, pcDNA3.3-SARS2-B1.617.2, and pcDNA3.3_SARS2_Omicron_BA.1 were provided by David Nemazee (Addgene plasmids #170674, #172320, #180375). GFP-PIPK1 gamma 90 was provided by Pietro De Camilli (Addgene plasmid #22299), and GFP-hPIKfyve was provided by Geert van den Bogaart (Addgene plasmid #121148). pcDNA3.1-ACE2-GFP was provided by Utpal Pajvani (Addgene plasmid #154962). mCherry-Rab5 and Rab7A were provided by Gia Voeltz (Addgene plasmids #49201, #61804), and mCherry-lysosomes-20 was provided by Michael Davidson (Addgene plasmid #55073). pMD2.G was provided by Didier Trono (Addgene plasmid #12259).

[0171]

[0172] mCherry-GFP-LC3 Tandem Fluorescent Protein Quenching Analysis

[0173] HEK293T cells were seeded in 96-well plates at a cell density of 1.6 × 10⁴ per well and stained with Hoechst (Cayman Chemical Company, 33342) for 10 minutes. Cells were washed twice with PBS and cultured in warmed medium containing 10% FBS. Cells were treated with UNI418 in warmed medium. Images were acquired in a time-dependent manner and quantified using the ImageXpress High-content Screening System (Molecular Devices).

[0174]

[0175] Endosome pH change test

[0176] This imaging-based experiment was performed with some modifications to a previous report. Vero cells were cultured overnight in glass-bottomed 35 mm dishes at a density of 6 × 10⁴ cells per well. The cells were treated with UNC3230, afilimod, or UNI418 (1 μM each) at 37°C for 1 hour. Subsequently, acridine orange (Sigma-Aldrich, A9231) was stained at a final concentration of 4 μg / mL for 30 minutes. After washing twice with PBS, images were acquired using a confocal microscope (Zeiss LSM 700) with 488 nm excitation and two emission windows at 493–560 nm and 590–720 nm. The green-to-red ratio or vacuole size was measured using ZEN 3.1 software.

[0177]

[0178] SARS-CoV-2 purification

[0179] SARS-CoV-2 (hCoV-19 / Korea / KCDC06 / 2020) belongs to the S clade, was provided by the Korea Disease Control and Prevention Agency, and amplified in Vero E6 cells (passage no. 4). The virus was concentrated for use in infection under conditions of high multiplicity of infection (MOI) as previously reported. Briefly, 30 mL of virus stock was loaded onto 6 mL of 20% sucrose, and ultracentrifugation was performed at 106,800 g for 16 hours at 4°C using a SW-32Ti rotor (Beckman Instruments). After removing the supernatant, the pellet was placed in 1.5 mL of DMEM and lysed overnight at 4°C. Viral titers were measured in Vero E6 cells by plaque assay and stored at -80°C until use. All experiments using infectious SARS-CoV-2 were conducted at KRICT's biosafety level 3 (BL3) facility.

[0180]

[0181] Preparation of SARS-CoV-2 spike pseudotype lentivirus

[0182] To generate a SARS-CoV-2 spike-pseudotype lentivirus containing luciferase, 5 × 10 6HEK293FT cells were co-transfected using branched PEI (Sigma-Aldrich) with 6 μg pBOBI-Fluc, 4.5 μg psPAX2, and 1.5 μg SARS-CoV2 spike plasmids (pcDNA3.1-SARS2-Spike for Wuhan-Hu-1, pcDNA3.3-SARS2-B1.617.2 for the Delta variant, and pcDNA3.3_SARS2_Omicron_BA.1 for the Omicron variant). The medium was replaced with fresh medium after 24 hours. Viral supernatants were harvested at 48 and 72 hours post-transfection. To package VSVG pseudoviruses, pMD2.G was co-transfected with all the aforementioned plasmids. For recombinant SARS-CoV2 spike, 5 × 10⁶ 6 HEK293T cells were co-transfected with 12 μg SARS-CoV2 HexaPro plasmid using branched PEI. After 24 hours, the supernatant was removed, replaced with fresh medium, and harvested in the same manner.

[0183]

[0184] Analysis of Virus Entry Using SARS-CoV-2 S-Pseudotype Virus and Luciferase Reporter

[0185] 1.5 × 10⁴ 293T-ACE2 cells were seeded in 96-well plates. Prior to viral infection (100 μL per well), the cells were pretreated with 0.5 μM UNI418 for 1 hour. After 12 hours of infection, the supernatant was removed and replaced with fresh medium. After harvesting the cells, luciferase activity was measured using the One-Glo Ex luciferase assay system (Promega Corporation, E8110) and at 24 hours post-infection using GloMax (Promega Corporation).

[0186]

[0187] Cytotoxicity and antiviral tests

[0188] To evaluate the cytotoxicity and antiviral activity of compounds including UNI418, afilimod, UNC3230, and remdesivir, Vero cells seeded in 96-well plates at a cell density of 3 × 10⁴ per well were either mock-infected or infected with SARS-CoV-2 (MOI: 0.01 for UNC3230, and 0.001 for UNI418, afilimod, and remdesivir). Each compound was treated at increasing concentrations ranging from 0.005 to 100 μM. After incubation at 37°C for 2 days, mock-infected cells were treated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylditetrazolium bromide (MTT) at a final concentration of 2.5 mg / mL for 3 hours at 37°C to measure cell viability. Absorbance was measured at 540 nm, and 690 nm was used as a reference. Half-cytotoxicity concentration (CC50) was defined as the concentration of a compound that reduces cell viability to 50% compared to cells treated with 0.2% DMSO.

[0189] Simultaneously, virus-infected cells were fixed and permeated with a cold acetone-methanol solution (1:3 ratio) at room temperature for 10 minutes. Viral spike proteins were detected with anti-spike antibodies (GeneTex) and Alexa 488-conjugated goat anti-mouse IgG (Invitrogen, A-11001), and nuclei were counterstained with DAPI (Vector Laboratories, H-1200-10). Fluorescent cells were counted using the Operetta High-content Screening System (Perkin Elmer). The half-effective concentration (EC50) was defined as the concentration of a compound that reduces the number of spike-positive cells by 50% compared to viral infection and 0.2% DMSO treatment conditions.

[0190] Exceptionally, because UNC3230 exhibited severe cytotoxicity on day 2, antiviral activity and cytotoxicity were measured on day 1. To evaluate combination therapy, Vero cells infected with an MOI of 0.01 were treated with UNC3230 and afilimod diluted three-fold at different ratios. The ratios were as follows: 5:0 (UNC3230 300 μM), 4:1 (UNC3230 240 μM + afilimod 60 nM), 3:2 (UNC3230 180 μM + afilimod 120 nM), 2:3 (UNC3230 120 μM + afilimod 180 nM), 1:4 (UNC3230 60 μM + afilimod 240 nM), and 0:5 (afilimod 300 nM). One day after infection, the fraction EC50 (FEC50) of UNC3230 and afilimod was calculated at each fixed ratio.

[0191]

[0192] Visualization of intracellular localization of NP and EEA1

[0193] Vero cells were cultured overnight in 4-well chamber slides at a density of 6 × 10⁴ cells per well. Subsequently, they were pretreated with 0.002% DMSO (mock), 1 μM UNI418, or 1 μM afilimod at 37°C for 1 hour. To synchronize viral infection, the medium was removed, and high-purity purified SARS-CoV-2 was infected in the presence of DMSO or each compound at 4°C for 30 minutes under an MOI of 10. Non-absorbed viruses were removed by washing twice with PBS and then cultured at 37°C under the same compound conditions. At 1, 2, 4, and 8 hours post-infection, cells were fixed with 4% paraformaldehyde for 10 minutes and permeated with 0.1% Triton X-100 for 5 minutes. For fluorescence microscopy analysis, viral nucleocapsid protein (NP) was stained with mouse anti-NP antibody and Alexa 488-conjugated goat anti-mouse IgG, and cellular EEA1 was detected with rabbit polyclonal anti-EEA1 antibody and Alexa 633-conjugated goat anti-rabbit IgG. Nuclei in all samples were counterstained with DAPI. Images were acquired using a confocal microscope (Zeiss LSM 700).

[0194]

[0195] Spike-RBD domain-induced receptor potential

[0196] 1.0 × 10⁶ HEK293T cells in a 35 mm confocal microscope dish 6Cells were seeded at cell density and transfected with 0.5 μg ACE2-GFP using branched PEI. After 24 hours, ACE2-expressing 293T cells were pretreated with 0.5 μM UNC3230, afilimod, or UNI418 in the presence of 20 μg / mL cycloheximide at 37°C for 30 minutes. Subsequently, 20 μg / mL of spike-RBD protein was added in the presence of cycloheximide and the same concentrations of the compounds, and the cells were incubated for the specified time. Images were captured at each time point using a confocal microscope (Zeiss LSM 880 with Airyscan; Carl Zeiss). The spike-RBD protein was provided by Ho Min Kim (Institute for Basic Science).

[0197]

[0198] result

[0199] UNI418 is a specific inhibitor of PIKfyve and PIP5K1.

[0200] UNI418 possesses a core structure composed of 4-quinazolinamine (Fig. 1a, green), which is a structure commonly found in kinase inhibitors. Treatment with UNI418 induced vacuolization in cells (Fig. 8), suggesting an important role in intracellular membrane transport. The phosphoinositide (PI) system acts as a critical regulatory mechanism in membrane transport and is strictly regulated via phosphorylation cascades by various phosphatidylinositol phosphate kinases (PIPKs). We hypothesized that UNI418 could inhibit PIPK(s) and performed PIPK profiling analysis. UNI418 inhibited PIP5K1B (93% inhibition at 1 μM, IC50: 60.7 nM), PIP5K1C (93% inhibition at 1 μM, IC50: 60.1 nM and Kd: 61 nM), PIKfyve (100% inhibition at 1 μM and Kd: 0.78 nM), and partially PIP5K1A (67% inhibition at 1 μM and IC50: 255 nM), indicating that UNI418 primarily targets PIKfyve and secondary targets PIP5K1B / C (Figs. 1b and 9).

[0201] To determine whether UNI418 interacts with PIP5K1C and PIKfyve, we performed a Cell Thermal Variation Analysis (CETSA), a method for measuring protein stabilization properties when a ligand binds to a target protein. After incubating cell lysates treated with UNI418 or DMSO at different temperatures, the presence of target proteins in the lysed fractions was analyzed by Western blotting (Fig. 1c). When treated with UNI418, exogenously expressed PIP5K1C and PIKfyve remained stable even at higher temperatures than the DMSO control group, indicating that UNI418 interacts with PIP5K1C and PIKfyve within the cell (Fig. 1c). Additionally, we confirmed that the level of PtdIns(4,5)P2 decreased upon treatment with UNI418 (Fig. 10), which is primarily synthesized by PIP5Ks.

[0202] Using a specific inhibitor of PIKfyve (apilimod) and a specific inhibitor of PIP5K1C (UNC3230), it was confirmed that vacuolation induced by UNI418 was positive for EEA1 (initial endosome marker) and LAMP1 (lysosome marker), which was similar to vacuolation induced by afilimod. On the other hand, UNC3230 did not induce vacuolation, indicating that vacuolation induced by UNI418 is mediated by PIKfyve (Figs. 11 and 12). Vaccination induced by UNI418 and afilimod gradually disappeared over time after washout, implying that the two compounds act reversibly (Fig. 12).

[0203]

[0204] UNI418 inhibits autophagy.

[0205] UNI418 specifically inhibits PIP5K1B, PIP5K1C, and PIKfyve, which have been reported as important regulators of lysosome transport and autophagosome-lysosome fusion. To determine whether UNI418 inhibits autophagy, we used a PIKfyve inhibitor (Afilimod) and a PIP5K1C inhibitor (UNC3230). Treatment with UNI418 and Afilimod led to significant accumulation of the autophagy monitoring proteins SQSTM1 / p62 (sequestosome 1)38 and LC3-II39 in RPE1 cells, which are indicators of autophagolysosomal turnover. In contrast, this effect was not observed with UNC3230 (Fig. 2a). Immunofluorescence staining also revealed that SQSTM1 / p62 (red) and LC3 (green) positive puncta significantly accumulated in RPE1 cells treated with UNI418 or afilimod, whereas this was not the case in cells treated with UNC3230 (Figs. 2b-c). Since autophagy flux refers to autophagic degradation activity, we measured the turnover rate of LC3-II to confirm whether UNI418 blocks autophagy flux. Lysosomal degradation was inhibited with bafilomycin A1 (BFA) to measure autophagy flux. Under normal medium conditions, treatment with 1 μM UNI418 significantly inhibited autophagy flux (Figs. 2d, e). The inhibitory effect of UNI418 was even more pronounced under cell starvation conditions using HBSS, and the autophagy flux increased by HBSS was strongly inhibited by UNI418 (Figs. 2d and e, Fig. 13).

[0206]

[0207] UNI418 inhibits autophagosome-lysosome fusion and endo-lysosome acidification.

[0208] PIP5Ks and PIKfyve are closely associated with autophagosome-lysosome fusion and endo-lysosome acidification. To investigate the effect of UNI418 on autophagosome-lysosome fusion, we used a pH-sensitive tandem-labeled mCherry-GFP-LC3 reporter. Since GFP loses fluorescence in acidic environments while mCherry retains it, mCherry-GFP-LC3 appears yellow (green + red) in non-acidic autophagosomes and red in acidic autolysosomes. Treatment with 0.5 μM UNI418 significantly increased the number of non-acidic autophagosomes within 6 hours (Figs. 3a-c), suggesting that UNI418 inhibits autophagosome-lysosome fusion or lysosomal acidification.

[0209] Acridine orange, a pH-sensitive dye, was used to monitor endo-lysosome acidification after UNI418 treatment. This dye emits green fluorescence in monomeric form at high pH and red fluorescence in dimeric form at low pH. Therefore, green fluorescence indicates high pH vesicles, and red fluorescence indicates low pH vesicles. When Vero cells were stained with aridine orange, red puncta were observed in the mock condition (Fig. 3d). Upon treatment with UNI418, green puncta increased significantly, which was similar to that of UNC3230 (Fig. 3d). The green to red ratio increased 2.6-fold in UNC3230 and 6.3-fold in UNI418 (Fig. 3e). An increasing trend was also observed with afilimod, but it was not statistically significant. Vaccine dilation induced by afilimod was also observed in UNI418 (Fig. 3f). These results suggest that UNI418 is a dual-function molecule targeting both PIP5K1C and PIKfyve, inhibiting endo-lysosome acidification and inducing vacuolation. This conclusion was confirmed in siRNA depletion experiments as well (Fig. 14a-e).

[0210] To distinguish deacidification in endosomes and lysosomes, we performed the same experiment using early / late endosome markers (mCherry-Rab5 / Rab7) and lysosome markers (mCherry-LAMP1). As shown in Figure 15, deacidification by UNI418 occurred in Rab7-positive late endosomes and LAMP1-positive lysosomes, and some small amount also occurred in Rab5-positive early endosomes, which may reflect transitional endosomes transitioning from the early stage to the late stage.

[0211]

[0212] UNI418 inhibits cathepsin maturation by interfering with PIKfyve-dependent lysosomal transport, which is associated with SARS-CoV-2 S protein cleavage.

[0213] Based on the observation that UNI418 treatment inhibits endo-lysosomal acidification (Figs. 3d and e, Fig. 15), we hypothesized that UNI418 treatment would inhibit the acid pH-dependent maturation of cathepsin within endosomes or lysosomes. To verify this hypothesis, we investigated whether UNI418 treatment inhibits the proteolysis of cathepsin D using a specific inhibitor of PIKfyve (Afilimod) and a specific inhibitor of PIP5K1C (UNC3230). Unlike the results regarding vesicular acidification (Figs. 3d and e), Afilimod significantly inhibited the proteolysis of cathepsin D, whereas UNC3230 did not (Fig. 4a). This result indicates that UNI418 inhibits the proteolysis of cathepsin via PIKfyve rather than through PIP5K1C-dependent vesicular acidification.

[0214] To investigate other possible mechanisms, we analyzed whether this cathepsin was correctly localized within lysosomes using a colocalization assay and detected cathepsin D and LAMP1 (lysosomal marker) together. As shown in Figures 4b and 4c, similar to afilimod, UNI418 treatment significantly reduced the lysosomal targeting of cathepsin D, which may be associated with non-lysosomal accumulation. On the other hand, UNC3230 did not show this effect, indicating that the phenomenon is mediated by PIKfyve.

[0215] To rule out the possibility that UNI418 is merely a lysosomotropic reagent, we investigated the accumulation of LAMP1 and LAMP1-positive lysosomes after treatment with UNI418 or chloroquine (a well-known lysosomotropic drug). Unlike chloroquine, UNI418 did not induce the accumulation of LAMP1 and LAMP1-positive lysosomes, which is a characteristic phenomenon observed in lysosomotropic drugs such as chloroquine. These results suggest that UNI418 is not merely a lysosomotropic substance (Figs. 16a-c).

[0216] The inhibitory effect of UNI418 on the proteolytic degradation of cathepsin D was reproduced in other cell lines, RPE1 and HCT116 (Figs. 17a-e), and the same was observed in cathepsin L of Vero cells, which are known to regulate SARS-CoV-2 infection (Figs. 4d and e, 18). In all experiments, UNI418 treatment significantly inhibited the protein maturation of both cathepsin D and cathepsin L.

[0217] Endosomal escape by SARS-CoV-2 depends on the process of proteolysis of the full-length S protein into its mature form, which occurs at least two cleavage sites mediated by host cathepsin L within the late endosome / lysosome. These sites are named CS-1 and CS-2, respectively, and are located near the N-terminal region of the S1 subunit and the purine cleavage S1 / S2 sites.

[0218] To determine whether UNI418 inhibits the proteolysis of the SARS-CoV-2 spike protein, we used an ectodomain-only SARS-CoV-2 spike HexaPro mutant protein (Spike-HexaPro), which possesses a mutation in the purine cleavage site while retaining other cleavage sites recognized by cathepsin L. HEK293T cells overexpressing hACE2 (hACE2-293T cells) were treated with Spike-HexaPro protein alone or in the presence of 0.5 μM UNI418, and Western blot analysis was performed at specific time points. In the DMSO-treated control group, cleavage at the CS-2 site was observed after 6 hours using an S2-specific antibody (Figs. 4f and g). In contrast, upon UNI418 treatment, the formation of the maturation product was delayed by 3 hours, appearing after 9 hours.

[0219] SARS-CoV-2 infection occurs through the binding of spike protein to ACE2 followed by membrane fusion, a process known to be accompanied by the internalization of ACE2 and downregulation at the cell surface. We also observed that UNI418 treatment of the same lysate alleviated the downregulation of ACE2 induced by the spike protein (Fig. 4f).

[0220]

[0221] UNI418 inhibits SARS-CoV-2 infection in Vero cells.

[0222] To evaluate the antiviral efficacy of UNI418 against SARS-CoV-2 infection, Vero cells were infected with the virus and treated with increasing concentrations of UNI418 using afilimod, UNC3230, and remdesivir as controls. Immunofluorescence analysis using anti-spike antibodies was performed on day 2 after infection (for UNI418, afilimod, and remdesivir) or day 1 (for UNC3230), and it was confirmed that viral infection was inhibited in a concentration-dependent manner by all compounds (Figs. 5a and 19). The EC50 value of UNI418 (1.4 μM) was the median value for afilimod (0.3 μM) and remdesivir (8.9 μM). We also compared cytotoxicity to determine the antiviral selectivity index (SI) of each compound. Under identical cell culture conditions, MTT-based cell viability analysis performed without viral infection showed that the CC50 value of UNI418 was 62.3 μM (SI calculated as the CC50 / EC50 ratio and 45.6), afilimod was 73.6 μM (SI, 272.6), and remdesivir was >100 μM (SI, >11.2). Unlike the three active compounds, UNC3230 exhibited high cytotoxicity on day 2, so its inhibitory effect was evaluated on day 1. As a result, UNC3230 showed very low activity with an EC50 of 95.1 μM and a CC50 of >100 μM. The overall antiviral and cytotoxicity data suggest that UNI418 is active against SARS-CoV-2 within the concentration range where cytotoxicity is not observed.

[0223] To confirm this inhibitory effect, we performed quantitative RT-PCR and Western blot analysis using SARS-CoV-2 infected culture supernatant and Vero cell lysate after treating with UNI418 at various concentrations ranging from 1 nM to 10 μM. As a result of measuring viral genome copy numbers, NP gene levels decreased by approximately 2-log due to UNI418 and afilimod at 10 μM treatment (Fig. 5b). Consistent with these results, the amount of viral NP decreased significantly as the concentration of UNI418 increased, which did not affect cellular β-actin expression (Fig. 5c). These data suggest that UNI418 effectively inhibits SARS-CoV-2 replication within cells as an antiviral agent and reduces the production of progeny viruses in the culture supernatant.

[0224] In addition, we investigated whether UNI418-induced endolysosomal deacidification and inhibition of cathepsin L maturation (Figs. 3d-e and 4d-4e) affect endosome escape during the entry phase of SARS-CoV-2. To this end, virus-infected cells were cultured with viral NPs and two primary antibodies specific to the cell's early endosome antigen 1 (EEA1), which were detected using secondary antibodies conjugated with Alexa 488 and Alexa 633, respectively (Figs. 5d and 20). Immunofluorescence analysis over time revealed that in DMSO-treated mock cells, viral NPs colocalized with EEA1 in the perinuclear region 1 hour after infection and separated after 2 hours. During one rotation of the viral life cycle (approximately 8 hours), newly synthesized viral NPs increased strongly in the cytoplasm (Fig. 5d, top panel and Fig. 20e).

[0225] In contrast, under UNI418 treatment conditions, the accumulation of NPs on the cell membrane inhibited not only endosome-mediated SARS-CoV-2 influx but also the release of NPs from endosome vesicles, and the size of these vesicles gradually increased in a time-dependent manner (Fig. 5d, middle panel and Fig. 20e). Interestingly, viral NPs were localized along the endosome membrane to which EEA1 was bound. Similar results were observed in afilimod-treated cells (Fig. 5d, bottom panel and Fig. 20e), which is consistent with recent reports that inhibition of PIKfyve kinase induces abnormal expansion and vacuolation of EEA1-positive endosomes, as well as blocking SARS-CoV-2 infection.

[0226] During the SARS-CoV-2 infection process, the binding of spike-ACE2 is known to promote ACE2 cleavage by TMPRSS2 and ADAM17, thereby inducing the production of ACE2 ectodomains. Conversely, this interaction induces the internalization of ACE2 for SARS-CoV-2 influx. Based on observations that viral particle-derived NPs accumulated on the cell membrane and endosome membrane in the presence of UNI418 (Fig. 5d, middle panel), we hypothesized that this compound could influence the cleavage or internalization of ACE2. To verify this hypothesis, we analyzed ACE2 levels and the treatment process in SARS-CoV-2 infected cells following UNI418 treatment using Western blot. Consistent with the hypothesis, full-length ACE2 (approx. 110 kDa) decreased 1 and 3 hours after infection, and ACE2 ectodomains of approximately 75 kDa appeared simultaneously (Fig. 6a). Interestingly, UNI418 treatment inhibited the endogenous full-length ACE2 reduction induced by SARS-CoV-2 infection in a concentration-dependent manner (Fig. 6a).

[0227] To verify the role of UNI418 in ACE2-mediated endocytosis, we observed the internalization of hACE2-GFP in HEK293T cells expressing hACE2-GFP after treating them with Spike-RBD for 1 or 2 hours. After 2 hours of treatment, hACE2-GFP was observed primarily in cytoplasmic vesicles, indicating ACE2-mediated endocytosis (Fig. 6b). UNC3230, UNI418, and Dynasaur inhibited ACE2-mediated endocytosis induced by Spike-RBD, whereas afilimod did not show a clear inhibitory effect (Fig. 6b). These results were consistent when quantifying the ratio of internalized hACE2-GFP to membranous hACE2-GFP signals in individual cells (Fig. 6c). These results suggest that UNI418 inhibits ACE2-mediated endocytosis of SARS-CoV-2, including spike-RBD, through PIP5K1C rather than PIKfyve.

[0228]

[0229] UNI418 inhibits the entry of SARS-CoV-2 spike-mediated pseudoviruses through PIP5K1C and PIKfyve.

[0230] To elucidate the role of UNI418 in inhibiting SARS-CoV-2 entry, we used a SARS-CoV-2 spike-pseudotype lentivirus system containing a luciferase reporter. In this system, non-replication lentiviruses carrying the SARS-CoV-2 spike protein were introduced into HEK293T cells expressing hACE2. This pseudovirus assay allows for the selective analysis of only the viral entry step mediated by the interaction between the SARS-CoV-2 spike and hACE2, excluding other infection steps such as genome replication or assembly. To ensure reliability and universal antiviral activity, we performed pseudovirus entry assays using Wuhan-Hu-1, delta (B.1.617.2), and omichron (BA.1) variant spike proteins and used VSV-G as a control. UNI418 treatment significantly inhibited the influx of Wuhan-Hu-1, delta, and omicron variant spike-pseudotype viruses (Fig. 7a). On the other hand, it did not affect the influx of VSV-G pseudovirus.

[0231] Based on the fact that UNI418 inhibits PIP5K1A, PIP5K1B, PIP5K1C, and PIKfyve (Fig. 1b), we investigated whether the depletion of each gene inhibits SARS-CoV-2 spike-mediated influx. Depletion of PIP5K1C and PIKfyve significantly inhibited SARS-CoV-2 spike-mediated influx (Fig. 7b-c), whereas depletion of PIP5K1A or PIP5K1B had no effect (Fig. 21a-b). These results strongly suggest that PIP5K1C and PIKfyve are proviral factors that promote SARS-CoV-2 cell influx.

[0232] To evaluate the synergistic effect of the dual inhibition of PIKfyve and PIP5K1C, we conducted pseudovirus influx experiments using afilimod (a PIKfyve inhibitor) and UNC3230 (a PIP5K1C inhibitor). First, we determined the concentrations that induce 50% inhibition relative to maximum inhibition, which were 5 nM for afilimod and 4 μM for UNC3230 (Figs. 21c-d). As shown in Fig. 7d, combined treatment with afilimod and UNC3230 inhibited SARS-CoV-2 spike-mediated influx more efficiently than treatment alone, indicating a synergistic effect of the dual inhibition of PIKfyve and PIP5K1C. This result was replicated in SARS-CoV-2 infected cells treated with different combination ratios (Fig. 7e). The ΣFEC50 value was found to be 0.68, which means that the two compounds act synergistically according to the criterion that a ΣFEC50 of less than 0.8 is considered synergy (Fig. 7f).

[0233] Collectively, UNI418 blocks SARS-CoV-2 ACE2-mediated endocytosis by reducing PtdIns(4,5)P2 levels at the cell membrane through PIP5K1C inhibition (Fig. 7g, Step 1). Additionally, UNI418 inhibits PIKfyve-mediated PtdIns(3,5)P2 synthesis, which is important for the protein maturation of cathepsin L. This inhibition prevents the spike protein from maturing into a fusion-ready form, thereby blocking the endosome escape of the SARS-CoV-2 genome (Fig. 7g, Step 2).

[0234]

[0235] Discussion

[0236] Since the emergence of SARS-CoV-2, which caused coronavirus disease in 2019, various neutralizing antibodies, vaccines, and therapeutic drugs have been developed or are currently undergoing clinical trials to protect against SARS-CoV-2 and its variants. While specific therapeutic strategies that directly target viral proteins are effective, they are often accompanied by a risk of failure due to rapid mutations in the viral RNA genome and the potential emergence of drug-resistant strains. Neutralizing antibodies and vaccines developed during the early epidemic phase showed reduced efficacy or diminished effectiveness in preventing the widespread transmission of variant viruses, including the Omicron variant. Therefore, it is important to develop additional small molecule-based antiviral agents with different chemical structures or mechanisms of action against SARS-CoV-2 infection. In this study, we propose UNI418 as a novel therapeutic compound that simultaneously targets PIP5K1C and PIKfyve (Fig. 5).

[0237] PIPK profiling analysis revealed that PIP5K1B, PIP5K1C, and PIKfyve were major targets of UNI418 (Fig. 1b), but genetic removal of PIP5K1B did not inhibit the influx of SARS-CoV-2 S-pseudotype virus into cells (Fig. 21a). On the other hand, depletion of PIP5K1C or PIKfyve successfully inhibited influx, suggesting that these two PIPKs may be functional targets exhibiting antiviral effects of UNI418 (Figs. 7b-c). Inhibition of PIKfyve (Afilimod) has been reported to inhibit cytoplasmic influx and infection by SARS-CoV-2. More recently, there have been reports that PIP5K1C mRNA transcription levels increase after SARS-CoV-2 infection in tonsil epithelial organoids established from human tissue. These early transcriptome analyses suggest that PIP5K1C may be primarily involved in the reorganization of cellular lipid metabolism during viral infection. In this study, PIP5K1C was identified as a potential target for inhibiting SARS-CoV-2 infection. Given the accumulated evidence supporting PIP5K1C as an effective target, it would be worthwhile to evaluate the antiviral efficacy of UNI418 using an ex vivo human organoid challenging model as a preclinical approach.

[0238] PIKfyve mediates the synthesis of lysosomal PtdIns(3,5)P2 and PtdIns(5)P, which is important for the function and homeostasis of late endosomes and lysosomes. The synthesis and turnover of lysosomal PtdIns(3,5)P2 mediated by PIKfyve are key regulatory mechanisms in autophagosome-lysosome fusion. We showed that inhibition of PIKfyve by UNI418 and afilimod induces inhibition of autophagosome-lysosome fusion (Figs. 2 and 3a-c). Additionally, lysosomal targeting of cathepsin and subsequent protein maturation were inhibited by UNI418 and afilimod (Figs. 4a-c), indicating that PIKfyve is involved in this process. Membrane fusion between SARS-CoV-2 and endosomes / lysosomes, and the subsequent endosome release of the viral genome, depend absolutely on the process of proteolysis of the spike protein into a mature fusion-capable protein by host cathepsin L within the late endosome / lysosome. We showed that UNI418 inhibits the maturation of cathepsin L (Figs. 4d-e), and as a result, delays the protein activation of the spike protein (Figs. 4f-g).

[0239] However, it has been reported that PIKfyve inhibitors, such as afilimod, can reduce antigen presentation by blocking the cell surface migration of MHC class II, and also negatively affect the production of Toll-like receptor (TLR)-mediated antiviral type I interferon by regulating activating transcription factor 3 (ATF3). Furthermore, in patients infected with SARS-CoV-2, this can further exacerbate already compromised T-cell immunity, potentially leading to a decrease in the production of inflammatory cytokines crucial to host defense mechanisms. Therefore, when using PIKfyve inhibitors as antivirals, dose optimization or combination therapy with immunostimulators may be necessary.

[0240] The PIP5K family, including PIP5K1A, PIP5K1B, and PIP5K1C, is a key enzyme involved in converting PtdIns4P to PtdIns(4,5)P2. This lipid is essential for clathrin-mediated endocytosis, which is a common pathway for viral entry. Therefore, we propose that UNI418 reduces PtdIns(4,5)P2 levels by locally inhibiting PIP5K1C (Fig. 10), thereby blocking SARS-CoV-2 ACE2-mediated endocytosis (Fig. 6). Additionally, we observed that UNI418 and UNC3230 induce deoxygenation of endolysosomes (Figs. 3d-e), and further investigation is needed regarding the relationship with the escape of the viral genome from the endosome. In addition, the reason why only PIP5K1C depletion, rather than PIP5K1A / B, inhibited the entry of SARS-CoV-2 spike-pseudotype viruses must also be further investigated. Based on these results, we propose that UNI418 inhibits SARS-CoV-2 infection through a multi-effect that simultaneously targets PIKfyve (inhibition of endosome escape) and PIP5K1C (inhibition of ACE2-mediated endocytosis).

[0241] In summary, we demonstrated that UNI418, a novel dual inhibitor simultaneously targeting PIKfyve and PIP5K1C, effectively inhibits SARS-CoV-2 infection at non-toxic concentrations. Mechanistically, UNI418 inhibits ACE2-mediated endocytosis and cathepsin L-mediated endosome escape. Our results suggest that pharmacological inhibition of PIKfyve and the novel target PIP5K1C could be an effective therapeutic strategy to prevent infection by SARS-CoV-2 and its variants and to prepare for future pandemics.

[0242]

[0243] Study 2: Overcoming Cul4A-WDR5-mediated Homologous Recombinant Protein Degradation and PARP Inhibitor Resistance by Inhibition of IP6 Signaling

[0244] abstract

[0245] Homologous recombination (HR) is an essential process for maintaining genomic stability and is strictly regulated. However, the role of ubiquitin-dependent degradation in HR proteins is not yet fully understood. In this study, compounds regulating the DNA replication stress response were screened to identify ML367 and its derivative, UNI418. Through kinase profiling and precise molecular analysis, it was confirmed that UNI418 reduces inositol hexaphosphate (IP6) levels by inhibiting PIKfyve and PIP5K1C, and induces Cul4A-dependent degradation of RAD51, CtIP, and CHK1. Further analysis identified WDR5 as a DCAF protein that promotes Cul4A-mediated protein degradation. Functionally, UNI418 inhibits HR, increases tumor sensitivity to PARP inhibitors (PARPi), and resensitizes PARPi-resistant tumors in in vitro and in vivo xenograft models. These results suggest a Cul4A-WDR5-dependent protein degradation pathway that regulates HR protein stability through phosphatidylinositol signaling. This mechanism offers a promising therapeutic strategy to overcome PARPi resistance and enhance combination cancer treatment strategies.

[0246]

[0247] result

[0248] Identification of UNI418, a compound that inhibits DNA replication stress response

[0249] In a previous study, we revealed that ML367 acts as an inhibitor of the DNA replication stress response induced by 5-fluorouridine (5-FUrd). Subsequently, we further screened approximately 100 derivatives structurally similar to ML367, yielding compounds with enhanced efficacy in alleviating DNA replication stress; among these derivatives, UNI418 was identified as the most effective substance (Fig. 22a, b). The ability of ML367 and UNI418 to attenuate DNA replication stress was quantitatively evaluated using the ATAD5-luciferase assay (Fig. 22c and Fig. 29a). In particular, UNI418 inhibited the DNA replication stress response induced by 5-FUrd more strongly than ML367, which was confirmed by a lower IC50 value for the inhibition of ATAD5-luciferase expression. These results were also supported by the decrease in serine 4 and 8 residue phosphorylation of RPA32 and CHK1 phosphorylation upon treatment with ML367 or UNI418 under DNA replication stress conditions such as camptothecin (CPT), hydroxyurea (HU), and 5-FUrd (Fig. 22d, e and Fig. 29b). Interestingly, UNI418 treatment reduced not only CHK1 phosphorylation but also the CHK1 protein level itself even under conditions without DNA replication stress, suggesting that UNI418 affects CHK1 expression. In summary, UNI418 is a compound that inhibits the DNA replication stress response.

[0250]

[0251] UNI418 inhibits PIKfyve and PIP5K1C.

[0252] UNI418 possesses a 4-aminoquinazoline core structure, which is a structural motif commonly observed in kinase inhibitors and exhibits affinity for the ATP binding pocket. Therefore, we hypothesized that UNI418 exerts biological effects through kinase inhibition. To identify the specific kinase targeted by UNI418, a comprehensive kinase profiling analysis was performed using the DiscoverX kinome profiling service. As shown in Figure 23a, the kinase profiling analysis revealed that UNI418 potently inhibited the lipid kinase PIKfyve. To verify this, a PIPK profiling analysis was performed, which showed that UNI418 inhibits PIP5K1B, PIP5K1C, and PIKfyve. The calculated dissociation constants (KD) for PIKfyve and PIP5K1C were 0.74 nM and 61 nM, respectively (Figure 23b). It is noteworthy that the third lipid kinase, PIP5K1B, showed only partial inhibition under test conditions (data not listed). In the kinase profiling analysis, UNI418 demonstrated inhibitory activity against an additional 11 kinases. Subsequently, a more precise evaluation of nine of these kinases was performed using Thermo Fisher Scientific's SelectScreen 11-point titration profiling analysis (Fig. 30a). As a result, no kinase exhibited IC50 values ​​in the range of 1 nM or less, similar to PIKfyve, while only CSF1R, FLT3, and MINK1 exhibited IC50 values ​​in the range of 100 nM or less, similar to PIP5K1C. Additionally, to identify potential off-target effects on these three kinases, including BUB1 and GCN2 which were not further analyzed in the profiling, CHK1 protein levels were investigated after depletion of each (Fig. 30b).Unlike the effect observed in PIKfyve depletion, inhibiting the expression of these kinases did not significantly decrease CHK1 levels.

[0253] Surface plasmon resonance (SPR) analysis was performed to confirm whether UNI418 directly binds to these lipid kinases. For this purpose, the maltose-binding protein (MBP)-tagged kinase domains of each protein were immobilized on a CM5 chip. The purity and integrity of the recombinant proteins were verified by SDS-PAGE analysis (Fig. 31a). Subsequently, UNI418 was injected as an analyte, and changes in resonance units (RU), reflecting molecular weight accumulation on the sensor surface, were measured. Sensorgrams were generated to visualize interaction kinetics, and blank subtraction was performed using injection signals containing only DMSO at the same concentration used for UNI418 dissolution to accurately measure UNI418-specific binding. This process eliminated refractive index changes and bulk shifts caused by DMSO, allowing for the evaluation of only the binding reactions induced by UNI418. The blank-removed sensogram data clearly demonstrated that UNI418 directly interacts with both PIKfyve and PIP5K1C, supporting the inhibitory activity of UNI418 against these lipid kinases (Fig. 23c). Almost no interaction was observed between MBP, used in the purification process, and UNI418 (Fig. 31b). Subsequently, we sought to confirm evidence that UNI418 binds to PIKfyve and PIP5K1C within cells; to this end, we used the Cell Thermal Variation Analysis (CETSA), which measures the degree of stabilization of proteins against thermal denaturation upon ligand binding. Cell lysates were treated with either UNI418 or DMSO and exposed to various temperatures, after which the amount of target proteins remaining in the soluble fraction was analyzed by Western blotting. As a result, PIKfyve and PIP5K1C, overexpressed after UNI418 treatment, remained stable even at higher temperatures than the DMSO-treated group (Fig. 23d).These observations suggest that UNI418 interacts with PIKfyve and PIP5K1C even within the cellular environment, supporting the in vitro results.

[0254]

[0255] UNI418 reduces the levels of intracellular phosphorylated inositol species.

[0256] Lipid kinases, including PIKfyve and PIP5K1C, play a crucial role in phosphorylating molecules containing inositol and function as secondary messengers in various cellular signaling pathways. Specifically, PIKfyve phosphorylates PI(3)P to produce PI(3,5)P2, while PIP5K1C phosphorylates PI(4)P and PI(3,4)P2 to produce PI(4,5)P2 and PI(3,4,5)P3, respectively (Fig. 23e). First, we analyzed phosphoinositide levels after treatment with UNI418 using the Creative Proteomics Lipidomics service. As a result, treatment with UNI418 or the PIKfyve inhibitor afilimod reduced the levels of PIP, PIP2, and PIP3 (Fig. 32a). Considering that PI(4,5)P2 is cleaved by phospholipase C to produce I(1,4,5)P3, which then undergoes further phosphorylation to produce more highly phosphorylated inositol species including I(1,2,3,4,5,6)P6 (IP6, inositol hexaphosphate), we hypothesized that UNI418 could inhibit the production of IP6 associated with the regulation of CHK1 protein levels. Consistent with this hypothesis, intracellular IP6, as well as IP3, IP4, and IP5 levels, were reduced upon treatment with UNI418, as well as with afilimod or UNC3230, which inhibit PIKfyve and PIP5K1C, respectively (Figs. 23f and 32b, c).

[0257] To identify the residues in PIKfyve and PIP5K1C that interact with UNI418, we modeled the potential interactions between these proteins and UNI418. Using the RosettaDock and AutoDock programs, respectively, we identified two possible interaction pockets in both PIKfyve and PIP5K1C: an ATP binding pocket and a predicted binding pocket (Fig. 33a). To determine which pocket UNI418 interacts with, amino acid substitutions were introduced into the corresponding sites. The purified mutant proteins were analyzed for interactions with UNI418 using CETSA. In PIKfyve, the ATP-binding pocket mutant (ABM) ABM1 (L2020A) lost interaction with UNI418, whereas mutants different from the wild-type (WT) protein, such as ABM2 (I2875A, K1877A), predicted binding pocket mutant (PBM)1 (D1951A), and PBM2 (K1953A, R1959A), maintained interaction with UNI418 (Fig. 33b). Similarly, in PIP5K1C, the ABM1 mutant (L320A) lost interaction with UNI418, whereas mutants different from the WT protein, such as ABM2 (Q186A, K188A), still interacted with UNI418 (Fig. 33c). Taken together, these results demonstrate that UNI418 interacts through the ATP-binding pockets of both PIKfyve and PIP5K1C. This is also consistent with the fact that UNI418 has a 4-aminoquinazoline core structure known to interact with the ATP-binding pocket.

[0258]

[0259] UNI418 treatment lowers CHK1 levels as well as RAD51 and CtIP and suppresses HR.

[0260] The fact that CHK1 protein levels themselves unexpectedly decreased upon UNI418 treatment, along with a decrease in CHK1 phosphorylation in response to DNA replication stress (Figs. 22d and 29b), suggests that inhibition of PIKfyve and PIP5K1C may activate proteasome degradation of CHK1. Previous studies have reported that Cul4A is involved in ubiquitinating various proteins in response to DNA damage and regulating CHK1 protein levels. To further explore this, we investigated whether UNI418 reduces CHK1 protein by activating protein degradation. First, we examined whether UNI418 treatment affected the levels of other DSB repair-related proteins. In addition to CHK1, the levels of RAD51 and CtIP also decreased after UNI418 treatment (Figs. 24a and 34a). BRCA1 levels also decreased slightly after UNI418 treatment. On the other hand, this decrease was not observed in other DSB repair proteins such as MRE11, Ku80, and DNA-PKcs.

[0261] CtIP and RAD51 are proteins essential for HR; CtIP initiates DNA end resection for ssDNA tail formation, while RAD51 binds to the resected ssDNA to form nucleoprotein filaments, facilitating homology search and strand intrusion. When DSBs are induced by ionizing radiation (IR), CtIP and RAD51 rapidly accumulate at the damage site. To evaluate the effect of UNI418 on HR efficiency, we investigated the accumulation of CtIP and RAD51 in DNA damage-induced foci after IR treatment. After 10 Gy IR treatment, RAD51 and CtIP formed distinct nuclear foci colocalized with γH2AX, a DNA damage marker. However, UNI418 treatment significantly reduced RAD51 foci formation and total nuclear RAD51 intensity (Fig. 34b), and also reduced CtIP foci formation (Fig. 34c), which was consistent with a decrease in protein levels (Figs. 24a and 34a). These results suggest that UNI418 reduces HR efficiency.

[0262] To further investigate the mechanism of HR inhibition mediated by UNI418, we analyzed the distribution and amounts of RAD51, CHK1, and CtIP in the chromatin and soluble fractions in the presence or absence of UNI418 following hydroxyurea (HU) treatment (Fig. 34d). UNI418 reduced the protein levels of RAD51, CHK1, and CtIP in both the soluble and chromatin fractions. This reduction was mediated by proteolysis, as the levels of RAD51, CHK1, and CtIP were restored upon co-treatment with the proteasome inhibitor MG132 (Fig. 24c). Notably, UNI418 treatment did not cause changes in the mRNA levels of RAD51, CHK1, and CtIP, implying that UNI418 specifically affects protein stability rather than transcriptional regulation (Fig. 34e). In a study of protein degradation kinetics using cycloheximide (CHX) chase experiments, it was further confirmed that UNI418 accelerates the degradation of HR protein compared to the control group (Fig. 24d).

[0263] Inositol polyphosphate multikinase (IPMK) has previously been reported as a key regulator involved in the conversion of I(1,4,5)P3 to I(1,3,4,5)P4 and subsequently to I(1,3,4,5,6)P5, and is also known to be involved in regulating the extranuclear transport of RAD51 mRNA. To investigate whether UNI418 affects RAD51 mRNA export, we isolated nuclear and cytoplasmic mRNA fractions from RPE1 cells treated with UNI418. After UNI418 treatment, there were no significant changes in the cytoplasmic levels of RAD51, CHK1, and CtIP mRNA, while only a slight increase in CHK1 and CtIP mRNA levels was observed in the nuclear fraction (Fig. 35a). Additionally, evaluation of mRNA localization using RAD51 RNA fluorescence in situ hybridization (FISH) revealed no significant changes caused by UNI418 treatment (Fig. 35b). These results suggest that UNI418 does not inhibit RAD51 mRNA transport, and therefore show that this is not the mechanism of action of UNI418 in regulating RAD51 expression.

[0264] Next, we investigated whether HR frequency was affected by UNI418 treatment. To this end, we used a DSB repair reporter assay that quantifies successful DSB repair via HR or non-homologous end joining (NHEJ) using GFP-based readouts following targeted cleavage induced by I-SceI restriction endonuclease. UNI418 treatment significantly reduced HR repair and had only a relatively minor effect on NHEJ repair (Fig. 24e). Notably, this degree of HR reduction was less pronounced than that observed in siRAD51-mediated depletion, which is consistent with the fact that RAD51 protein is partially reduced by UNI418 (Fig. 35c).

[0265] Finally, we investigated whether UNI418 induces cell sensitivity under PARP1 deficiency or the PARP inhibitor olaparib conditions. To measure the IC50 of UNI418, which selectively targets PARP1-deficient cells, we used colon tumor HCT116 cells and isogenic PARP1-deficient cells constructed with target gene deletions (HCT116 PARP1 - / - Cells (Fig. 35d) were treated with various concentrations of UNI418, and cell viability was measured. As a result, HCT116 and HCT116 PARP1 - / - The IC50 of UNI418 in cells was measured to be 1.65 ± 0.23 μM and 0.44 ± 0.04 μM, respectively (Fig. 24f). Furthermore, UNI418 treatment showed higher HCT116 PARP1 than WT cells. - / - It induced a greater degree of apoptosis in the cells (Fig. 24g). To determine the basis of this concentration-dependent hypersensitivity, we performed a dose-response assay of UNI418 (0–5 μM) and measured the levels of RAD51, CHK1, CtIP, Cul4A, and γH2AX in the two cell populations (Fig. 36a). HR-related proteins decreased gradually and in a concentration-dependent manner in WT cells, whereas PARP1 - / - In cells, it decreased more rapidly and distinctly even at lower UNI418 concentrations. At the same time, γH2AX accumulation was higher in PARP1 cells than in WT cells. - / - It increased significantly in cells. These results indicate that the reason PARP1-deficient cells are more sensitive to UNI418 is not due to non-specific off-target toxicity, but rather because of greater HR dependence on genome maintenance. PARP1 - / -Consistent with the enhanced efficacy of UNI418 on cells, synergistic cytotoxic effects were observed in HCT116 WT cells when UNI418 and olaparib were combined, and apoptosis also increased (Figs. 24h, i and 36b). In addition, as the olaparib concentration increased, the combination index calculated by the CompuSyn algorithm became less than 1, demonstrating a synergistic effect (Fig. 36c). Taken together, these results suggest that UNI418 promotes the proteolysis of RAD51, CHK1, and CtIP, thereby impairing HR repair mechanisms and consequently increasing cytotoxicity under PARP1 inhibition conditions.

[0266]

[0267] Inhibition of PIKfyve and PIP5K1C lowers HR.

[0268] To determine whether PIP5K1C and PIKfyve, lipid kinases inhibited by UNI418, actually mediate the proteasome degradation of RAD51, CHK1, and CtIP inducible by UNI418, we conducted experiments to deplete these kinases using siRNA. Treatment with siRNA targeting PIP5K1C or PIKfyve resulted in a significant decrease in RAD51, CHK1, and CtIP protein levels, similar to those observed with UNI418 treatment (Fig. 25a, b). Furthermore, under PIKfyve depletion conditions, UNI418 treatment did not further reduce RAD51, CHK1, and CtIP levels. In contrast, the depletion of PIP5K1B did not induce distinct changes in RAD51 or CHK1 protein levels. In addition, consistent with the decrease in HR protein, depletion of PIP5K1C and PIKfyve significantly reduced HR efficiency, but depletion of PIP5K1B did not (Fig. 25c).

[0269] Next, we investigated whether inhibition of PIP5K1C and PIKfyve affects cell sensitivity to the PARP inhibitor olaparib. Cells depleted of each kinase individually showed increased sensitivity to olaparib compared to the control group, and simultaneous depletion of both kinases resulted in a more significant decrease in cell viability, suggesting an additive effect between PIP5K1C and PIKfyve (Fig. 25d). Under the CellTiter-Glo viability assay conditions following 72 hours of olaparib treatment, BRCA2-deficient cells also showed increased sensitivity to olaparib, with a magnitude of decrease similar to that observed when PIP5K1C and PIKfyve were simultaneously depleted. However, in the clonal viability assay involving longer-term exposure to olaparib, BRCA2-deficient cells exhibited much stronger hypersensitivity, consistent with the normal HR-deficient phenotype (Fig. 36d). Importantly, UNI418 treatment alone reduced cell viability to a level similar to that of single or double depletion of PIP5K1C and PIKfyve, and no further reduction was observed even with additional depletion of the kinases (Fig. 25e). This non-additiveness implies that the genetic depletion of UNI418, PIP5K1C, and PIKfyve acts through the same functional pathway, supporting the idea that inhibition of PIP5K1C and PIKfyve activity serves as a common mechanism. Taken together, these results demonstrate that UNI418 affects RAD51, CHK1, and CtIP through the inhibition of PIKfyve and PIP5K1C. The fact that HR protein levels and HR efficiency decreased and olaparib sensitivity increased due to the depletion of these kinases highlights that PIKfyve and PIP5K1C play a key role in UNI418-induced DSB repair changes and DNA damage responses.

[0270]

[0271] Decrease in IP6 levels regulates the degradation of Cul4A-dependent HR proteins.

[0272] Cul4A is an E3 ubiquitin ligase that promotes the degradation of target proteins. The activity of Cul4A is strictly regulated by neddylation, and this post-translational modification increases the ability to recruit substrate adapters and promote ubiquitination. Previous studies have reported that Cul4A is involved in the ubiquitination of various proteins, including CHK1, in DNA damage responses. We explored the potential involvement of Cul4A in the proteasome degradation of RAD51, CHK1, and CtIP in response to changes in IP6 levels induced by UNI418. Treatment with UNI418 increased the ratio of neddylated Cul4A to deneddylated Cul4A (Fig. 26a). Conversely, supplementing cells or cell extracts with IP6 counteracted the Cul4A neddylation induced by UNI418 (Figs. 26a and 37a). In addition, similar to UNI418 treatment, the depletion of PIP5K1C and PIKfyve also increased the proportion of nedylated Cul4A (Fig. 26b). Importantly, neither UNI418 treatment nor the depletion of PIKfyve or PIP5K1C increased the absolute amount of nedylated Cul4A. Instead, both conditions increased the ratio of nedylated Cul4A to denedylated Cul4A, as reported in previous studies. These observations suggest the possibility that denedylated Cul4A plays an inhibitory role against nedylated Cul4A, or that nedylated Cul4A rapidly ubiquitinated the substrate, leading to turnover.

[0273] To determine whether Cul4A can directly regulate HR proteins such as RAD51 and CtIP, we investigated the effects of Cul4A depletion in the presence of UNI418. Depletion of Cul4A using siRNA increased the levels of RAD51, CHK1, and CtIP compared to the control group (Fig. 26c). In contrast, these increases were less pronounced under UNI418 treatment conditions. These results suggest that Cul4A is responsible for the degradation of RAD51, CHK1, and CtIP upon UNI418 treatment. Furthermore, supplementing cells with IP6 antagonized UNI418-induced HR protein degradation and promoted RAD51 foci formation after IR treatment (Figs. 26a, e, and 37b). The frequency of HR, which had been reduced by UNI418, was also restored by the additional supplementation of IP6 (Fig. 26e). Moreover, PARP1 in the presence of IP6 - / - UNI418 hypersensitivity of the cells was completely suppressed, indicating that a decrease in IP6 levels is a key contributing factor to UNI418-induced HR defects (Fig. 37c). However, IP6 was lower than that of WT and PARP1 - / - It is important to note that toxicity was observed in all cells.

[0274] Inositol-pentakisphosphate-2-kinase (IPPK) plays a key role in catalyzing the conversion of IP5 to IP6. To determine whether UNI418 acts primarily through the reduction of IP6 levels, we predicted that IPPK depletion would replicate the effects of UNI418 treatment. Indeed, depleting IPPK with siRNA (Fig. 37f) reduced HR protein levels even without UNI418 treatment (Fig. 37d). Furthermore, IPPK-depleted cells exhibited increased sensitivity to olaparib, similar to that observed with UNI418 treatment (Fig. 37e).

[0275]

[0276] WDR5 is the DCAF of Cul4A for the proteolysis of RAD51 and CHK1.

[0277] The substrate specificity of Cul4A is determined by interacting proteins called DCAFs. With over 60 known predicted DCAFs, we sought to identify the DCAF responsible for RAD51 protein degradation. To this end, we monitored RAD51 and CHK1 levels while screening siRNAs for available DCAF genes. As a result, RAD51 and CHK1 levels consistently increased when WDR5 was silencing (Fig. 27a). Conversely, WDR5 depletion did not increase CtIP levels, suggesting that CtIP is regulated by other DCAFs. Further proteasome inhibition using MG132 amplified the observed effects, suggesting that the remaining protein levels due to the incomplete depletion of WDR5 and Cul4A may have masked the complete recovery of RAD51 and CHK1. Consistent with the role of WDR5 as a potential DCAF for Cul4A, simultaneous silencing of Cul4A and WDR5 did not further increase RAD51 and CHK1 levels. However, while WDR5 depletion increased RAD51 and CHK1 levels, WDR5 overexpression did not induce a decrease in the opposite direction (Fig. 27b). Substrates of E3 ubiquitin ligases are known to transiently interact with their own E3 ligases. We investigated the potential interactions between WDR5, RAD51, and CHK1 and confirmed that in the presence of MG132, WDR5 can pull down not only RAD51 and CHK1 but also Cul4A and its interaction partner, DDB1 (Fig. 27b). To evaluate whether a weak increase in RAD51 and CHK1 levels affects PARPi sensitivity, cell survival was measured after treatment with high concentrations of olaparib following silencing of WDR5, Cul4A, or both. WDR5, Cul4A, or simultaneous silencing of both conferred resistance to olaparib (Fig. 27c).In summary, we confirmed that WDR5 is a key factor determining the protein degradation of RAD51 and CHK1 via Cul4A and emphasized its regulatory role in HR.

[0278] RFWD3 has previously been reported as an E3 ligase that promotes the degradation of RAD51 after HR is completed. To determine whether both RFWD3 and Cul4A contribute to RAD51 protein degradation, we evaluated RAD51 levels after depleting RFWD3 and Cul4A with siRNA, either individually or simultaneously (Fig. 37g). Cul4A silencing increased RAD51 levels under both basal and IR-induced conditions (Fig. 27d). In contrast, RFWD3 depletion induced RAD51 accumulation only under IR-induced conditions. Furthermore, simultaneous silencing of RFWD3 and Cul4A did not increase RAD51 levels more than under conditions of individual depletion alone. These results suggest that while Cul4A regulates RAD51 homeostasis under normal physiological conditions, RFWD3 primarily mediates RAD51 degradation during DNA damage responses.

[0279]

[0280] UNI418 inhibits tumor growth in PARP1-deficient tumors and enhances the effect of PARPi in combination therapy.

[0281] Based on the hypothesis that the excellent efficacy of UNI418 in killing PARP1-deficient cells and its synergistic effect with PARPi in vitro (Figs. 24g, h, i, j) may also exhibit effective antitumor activity in vivo, we performed a series of tumor xenograft experiments. For this purpose, WT or PARP1 - / - HCT116 cancer cells male NOD.CB17-Prkdc scidXenograft tumors were formed by transplantation into / J mice. When the tumor diameter reached approximately 0.5 cm, 4 ml / kg of vehicle or 10 mg / kg of UNI418 was administered directly into the tumor every other day for 12 days. Consistent with the initial hypothesis, UNI418 administration did not show a significant effect in WT tumors, but PARP1 - / - Tumor growth was significantly inhibited only in xenografts (Fig. 28a). Additionally, co-administration of olaparib 50 mg / kg and UNI418 10 mg / kg inhibited HCT116 tumor growth, an effect not observed when the two drugs were administered alone (Fig. 28b). Importantly, no significant change in mouse body weight was observed during the treatment period, regardless of whether a placebo or active drug was administered (Fig. 38a). Meanwhile, the pharmacokinetic data for UNI418 were not yet at a level suitable for immediate therapeutic application, suggesting that further development is required for clinical application (Fig. 38b). Taken together, these results demonstrate that UNI418 can be a promising therapeutic strategy applicable not only to PARP1-deficient cancers but also to a wider range of tumor types, particularly when combined with olaparib.

[0282]

[0283] UNI418 kills olaparib-resistant ovarian cancer cells.

[0284] BRCA1 or BRCA2-deficient ovarian and breast cancers are known to be sensitive to PARP inhibitors such as olaparib. However, in actual treatment, PARPi-resistant tumors frequently occur, posing a significant clinical problem. In this regard, PEO-1 and Capan-1 cell lines derived from BRCA2-deficient ovarian adenocarcinoma and pancreatic ductal adenocarcinoma showed sensitivity to PARPi treatment (Fig. 28c, f). However, C4-2 and C2-2 clones derived from PEO-1 and Capan-1, respectively, which carry BRCA2 reversion mutations, exhibited resistance to PARPi, reflecting a key mechanism of treatment evasion. UNI418 PARP1 - / - Considering that it acts selectively on cells (Fig. 24g, h), we hypothesized that UNI418 could effectively target PARPi-resistant cancer cells and resensitize tumors that had acquired resistance via BRCA2 conduction mutations to PARPi. Indeed, consistent with this hypothesis, the PARPi-resistant clones C4-2 and C2-2 showed higher sensitivity to UNI418 than their parent cells, PEO-1 and Capan-1, respectively (Fig. 28d, g). Furthermore, the combination of UNI418 and olaparib significantly increased the olaparib sensitivity of PARPi-resistant C4-2 and C2-2 cells, a phenomenon that was more pronounced when compared to parent cells treated with olaparib alone (Fig. 28e, h and Fig. 39). Crucially, this increase in drug sensitivity was observed in parallel with a significant increase in apoptosis in PARPi-resistant C4-2 cells after UNI418 treatment (Fig. 28i). Taken together, these results show that UNI418 has significant potential as a therapeutic agent capable of overcoming one of the representative acquired resistance pathways to PARPi treatment in BRCA-deficient tumors.

[0285] In summary, our results demonstrate that UNI418 acts by inhibiting PIKfyve and PIP5K1C, thereby reducing IP6 levels. The reduction in IP6 levels increases Cul4A nedylation, which consequently activates the E3 ligase pathway. Activated Cul4A initiates the degradation of HR proteins, ultimately inducing HR defects. In particular, the key recombinases RAD51 and CHK1 become targets of Cul4A, the specificity of which is determined by the DCAF WDR5. Importantly, these HR defects make PARPi-resistant cells hypersensitive to UNI418 treatment. This comprehensive understanding of the molecular mechanism of UNI418 action provides significant insights into its potential therapeutic applications for the treatment of PARPi-resistant cancer (Fig. 28j).

[0286]

[0287] Discussion

[0288] Compounds discovered through phenotypic screening have proven to be useful tools for elucidating biological pathways and advancing clinical applications for disease treatment. Anticancer agents targeting DNA replication and cell proliferation have played a significant role in revealing the fundamental principles of DNA repair and cell division. For example, research on the natural product rapamycin has contributed to elucidating the mTOR signaling pathway, a central regulator of cellular metabolism. Therefore, UNI418 is not only a promising therapeutic candidate but also a molecular tool capable of revealing the regulatory axis between phosphoinositide metabolism and HR.

[0289] Through this study, we discovered an intriguing link between the DSB repair pathway and the inositol phosphate pathway, which were previously studied separately. In particular, inositol phosphate plays a crucial role as a cofactor regulating mRNA transcription, transport, and protein degradation within the nucleus. A representative example of inositol phosphate's specific involvement within the nucleus is its regulation through the denedylation of Cul4A by IP6. Along with this study, previously reported research on the regulation of E3 ubiquitin ligases by inositol phosphate suggests the possibility that multiple ubiquitin ligases are similarly regulated by inositol phosphate to control intracellular protein levels. If so, cellular signaling could effectively regulate protein homeostasis through protein degradation.

[0290] Our results demonstrate that a direct reduction in IP6 is the primary driver of Cul4A activation, resulting in the degradation of HR proteins. This aligns with observations that depleting IPPK, the enzyme that converts IP5 to IP6, leads to decreased levels of RAD51, CHK1, and CtIP, as well as increased cellular PARPi sensitivity. Recently, the anthelmintic Suramin and its derivative NF449 have been identified as potent inhibitors of IPPK. Cul4A plays a crucial role in the ubiquitination of various substrates in conjunction with its interacting protein, DDB1. DCAFs, another component of this complex, determine substrate specificity. Representative DCAFs of the Cul4 complex include DDB2, CSA, and COP1, which ubiquitinate XPC; these are involved in nucleotide excision repair and the regulation of DNA damage checkpoint pathways. Over 60 additional DCAFs have been identified, sharing multiple common domain structures and are believed to function as substrate receptors for Cul4 proteins. The confirmation in this study that WDR5 is associated with the selective Cul4A-dependent degradation of RAD51 suggests the possibility of the existence of specific DCAFs responsible for the degradation of various DNA metabolic proteins.

[0291] UNI418, which restores PARPi sensitivity in PARPi-resistant tumors, inhibits two lipid kinases, PIKfyve and PIP5K1C. CHK1, a key effector of the replication stress response, is known to exhibit synergistic effects with PARPi. Accordingly, UNI418 partially reduces the levels of CHK1, RAD51, and CtIP; however, the simultaneous reduction of these multiple HR components induces distinct HR defects despite relatively moderate depletion. Furthermore, genetic depletion of PIKfyve or PIP5K1C did not show additive effects with UNI418 treatment, which is consistent with a common mechanism mediated by IP6-dependent Cul4A activation rather than independent checkpoint inhibition. Therefore, compounds capable of inhibiting IP6 production by targeting PIKfyve, PIP5K1C, or IPPK can synergistically increase cellular sensitivity to PARPi therapy by simultaneously destabilizing the HR network.

[0292] Tumor regression induced by UNI418 may depend not only on HR protein degradation but also on pleiotropic effects associated with the inhibition of PIKfyve and PIP5K1C. These lipid kinases are involved in regulating the production of PI(3,5)P2 and PI(4,5)P2, which are essential for endosome and lysosomal membrane dynamics and autophagy activation. Therefore, disruption of cellular homeostasis by UNI418 may also contribute to the observed antitumor response. It is also worth noting that PIKfyve inhibitors with non-specific targets are not uncommon. Phosphatidyl inositol phosphates (PPIns) are involved in various cellular functions such as cell growth, proliferation, motility, intracellular transport, and survival. Consistently, inhibition of PIKfyve and PIP5K1C by UNI418 also inhibits the cellular influx of SARS-COVID-19, which is dependent on endocytosis and influenced by inositol phosphate signaling. Notably, when IP6 binds to the ubiquitin ligase Cul4A, it induces Cul4A denedylation, thereby inactivating E3 ubiquitin ligase function. Recent studies have demonstrated that PPIns play a crucial role in DSB repair and the regulation of the DNA damage response (DDR). For example, IPMK, which is critical for the biosynthesis of inositol 1,3,4,5,6-pentakisphosphatate, regulates the extranuclear transport of RAD51 mRNA in response to DNA damage and is also required for the recruitment and activation of ATRs in cooperation with phosphatidylinositol 3-phosphate. In addition, inhibition of phosphoinositide-3-kinase induces severe DNA damage in DDR-deficient tumors through nucleoside depletion. There are also reports that IP6 promotes NHEJ repair when it binds to DNA-PKcs.Although UNI418 lowers intracellular IP6 levels, considering the slight decrease in NHEJ activity upon UNI418 treatment (Fig. 24e) and the lack of distinct changes in Ku80 recruitment kinetics to DNA damage sites after IR treatment, it appears to have no significant effect on DNA-PKcs-dependent NHEJ. In summary, our results reveal a novel layer of DSB repair regulation through the complete or partial inhibition of PIKfyve and PIP5K1C, which affects HR-dependent DSB repair pathways and reduces HR enzymes.

[0293] In addition to these mechanistic findings, recently accumulating evidence suggests that IP6 metabolism itself may vary depending on the cancer type. Although UNI418 does not directly target IP6K or IPMK, abnormal regulation of these upstream enzymes is associated with tumor biology and clinical prognosis. IP6K2 functions as a tumor suppressor in breast cancer, whereas increased expression of IP6K1 is associated with aggressive recurrence and poor survival rates. These data suggest that different nodes within the inositol phosphate network are utilized differently depending on the tumor. Therefore, tumors that rely heavily on HR and the IP6 metabolic network may be particularly vulnerable to drugs like UNI418 that reduce the intracellular IP6 pool. In the future, performing comparative metabolomics and genomics analyses across different tumor lineages will be essential to predict UNI418 sensitivity and define biomarkers that can guide clinical application. Taken together, these results establish a mechanistic link between inositol phosphate signaling, HR dependence, and vulnerability to available treatments in DNA repair-dependent cancers, particularly those with BRCA dysfunction or PARPi resistance.

[0294] Triple-negative breast cancer (TNBC) with BRCA1 / 2 defects exhibits an aggressive nature and a poor 5-year prognosis. These TNBC subtypes respond well to PARPi. However, recent clinical trials and observational studies indicate that many patients acquire chemoresistance after long-term PARPi treatment. Several mechanisms are involved in PARPi resistance, including drug release mechanisms commonly observed in recurrent drug-resistant tumors. Furthermore, PARPi-resistant tumors also manifest through the activation of alternative recombination-related pathways, including HR, protection of DNA replication forks, and ssDNA gap repair. Since most PARPi resistance is explained by these alternative recombination-related mechanisms, targeting these pathways in PARPi-resistant tumors is a promising strategy. Indeed, inhibiting recombination-related mechanisms has a greater impact on survival rates in PARPi-resistant tumors than in normal cells. Several inhibitors, such as Mirin, which inhibits MRE11, and B02, which inhibits RAD51, have demonstrated efficacy in blocking these recombination-related mechanisms. In addition to these inhibitors, UNI418, which indirectly regulates recombinant proteins by acting on lipid kinases, can also be an alternative approach for treating PARPi resistance.

[0295] It is noteworthy that although BRCA2-transmitted cells had recovered HR function, they responded more sensitively to UNI418 than parent cells with BRCA2 defects. Tumors with BRCA-transmitted cells often experience persistent replication stress because they still preserve genomic instability derived from past BRCA loss. Since these cells still rely heavily on HR and replication stress response machinery, they are disproportionately vulnerable to Cul4A-mediated HR protein degradation. Indeed, UNI418 induced selective apoptosis and strong synthetic lethality in BRCA-transmitted cells when combined with olaparib (Fig. 28i).

[0296] In summary, this study elucidated the molecular mechanism by which HR is regulated by Cul4A-dependent degradation of the HR protein through the modulation of the inositol phosphate pathway using UNI418 as a tool compound. Furthermore, by selectively degrading the HR protein, we demonstrated that UNI418 is a compound active against PARPi-resistant tumors. Since targeting lipid kinases enhances PARPi efficacy in resistant tumors, monotherapy targeting the inositol phosphate pathway or combination therapy with PARPi and lipid kinase inhibitors can be promising strategies for overcoming PARPi-resistant tumors. Moving forward, clinical application for PARPi-resistant tumors may become possible through the optimization of UNI418 derivatives and the identification of IP6 metabolic biomarkers. Therefore, our results establish the inositol phosphate axis as an uncharted therapeutic platform for inducing HR dependence and overcoming PARPi resistance.

[0297]

[0298] Experimental method

[0299] The abbreviations and full names used in this study are summarized in Fig. 40.

[0300]

[0301] cell culture

[0302] HCT116 cells were provided by Eric Hendrickson's laboratory, and HCT116 PARP1 - / - Cells were prepared in this laboratory. HEK293T and U2OS were provided by ATCC, RPE1 by the Medical College of Georgia, and PEO-1, C4-2, Capan-1, and C2-2 by the Toshiyasu Taniguchi laboratory. HCT116, HCT116 PARP1 - / -HEK293T, U2OS, PEO-1, C4-2, Capan-1, and C2-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 100 U / mL penicillin G, and 100 μg / mL streptomycin. RPE1 cells were cultured in DMEM / F12 containing 10% fetal bovine serum, 100 U / mL penicillin G, and 100 μg / mL streptomycin.

[0303]

[0304] compound

[0305] The following reagents were purchased from Sigma-Aldrich: HU (H8627), 5-FUrd (F5130), MG132 (C2211-5 mg), the ATR inhibitor VE821 (SML1415), and IP6 (593648). Olaparib was purchased from Selleckchem. ML367 and UNI418 were synthesized in the laboratory according to the previously described method.

[0306]

[0307] Luciferase Assay

[0308] HEK293T cells expressing Luc-ATAD5 3 × 10 5 Cells were dispensed into each well of a 6-well plate and allowed to attach for 24 hours. Subsequently, the indicated compounds were treated for 24 hours. After harvesting the cells, luciferase activity was measured using Promega’s Dual-Luciferase Reporter Assay System (E1910). Luminescence signals were measured using a Synergy NEO2 Hybrid Multi-Mode Reader (Biotek).

[0309]

[0310] Western blot analysis

[0311] Whole-cell extracts were prepared by lysing harvested cells with M-PER mammalian protein extract reagent (Thermo). Protein concentration was measured using the Bradford protein assay (Bio-Rad). 20–30 μg of the prepared protein was separated by SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk for 30 minutes at room temperature. Subsequently, it was incubated overnight at 4°C with the primary antibody against the protein of interest. After washing with TBS-T, it was reacted with the secondary antibody for 1 hour at room temperature. Images were detected using an Odyssey imaging system (LI-COR Biosciences) or ChemiDoc (Bio-Rad).

[0312]

[0313] antibodies

[0314] The following antibodies were used for Western blotting and immunofluorescence staining. Rabbit polyclonal RAD51 (CST, #8875, 1:1000), phosphorylated RPA32 serine 4 and 8 (Bethyl, A300-245A, 1:1000), histone H3 (Millipore, #07-690, 1:1000), CtIP (CST, #9201S, 1:1000), GAPDH (abcam, ab181603, 1:1000), Cul4A (CST, #2699, 1:1000), PIP5K1C (CST, #3296, 1:1000), HSP90 (CST, #4874S, 1:1000), GFP (abcam, ab32146, 1:1000), mouse monoclonal CHK1 (CST, #2360, 1:1000), α-tubulin (Santa Cruz, sc-32293, 1:1000), β-actin (Sigma-Aldrich, A3853, 1:1000), WDR5 (CST, #13105S, 1:1000), PIP5K1B (Santa Cruz, sc-514169, 1:1000), and PIKfyve (Millipore, MABS522, 1:1000) were used. Human ATAD5 antibodies were synthesized in Rabbit using the N-terminal fragment (1-297 aa) and used at a 1:1000 ratio.

[0315]

[0316] SelectScreen Kinase Assay

[0317] Kinase assays were performed using Thermo Fisher Scientific's SelectScreen kinase profiling platform. Kinase-tagged T7 phages were produced from E. coli BL21-derived hosts, and additional kinases were expressed in HEK293 cells and DNA-tagged for qPCR detection. Streptavidin-coated magnetic beads were reacted with biotinylated small molecule ligands to create affinity resins, which were then blocked with a buffer to minimize non-specific binding. The binding reaction was prepared by mixing the kinase, ligand-coupled beads, and test compound in a binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween-20, 6 mM DTT). The test compound was treated with an 11-point 3-fold perpetual dilution, and the final DMSO concentration was 0.9%. The reaction was carried out in a 384-well plate with a total volume of 20 μL at room temperature for 1 hour. Afterward, the beads were washed and resuspended in an elution buffer containing 0.5 μM of non-biotinized ligand. The eluted kinase concentration was quantified by qPCR, and the dissociation constant (KD) was calculated from the concentration-response curve.

[0318]

[0319] Surface Plasmon Resonance (SPR)

[0320] SPR experiments were performed using a Biacore T200 instrument. 10 mg / ml of purified protein was diluted in 10 mM sodium acetate (pH 5.0) and immobilized on a CM5 chip (GE Healthcare) using the standard amine coupling method. HBS-EP+ buffer, consisting of 0.1 M HEPES, 1.5 M NaCl, 0.03 M EDTA, and 0.5% v / v Surfactant P20, was used as the execution buffer. After protein immobilization, UNI418 was prepared at various concentrations by diluting it in PBS-P20 and 5% DMSO solution. UNI418 was injected into the channel, and the binding reaction was measured in resonance units (RU).

[0321]

[0322] Cloning, protein expression, and purification

[0323] The genes encoding the kinase domains of human PIKfyve and PIP5K1C were amplified from the GFP-hPIKfyve and GFP-PIPK1 gamma 90 (GFP-PIP5K1C) plasmids (#121148, #22299) purchased from Addgene. The amplified genes were cloned into the expression vector pVFT4S, which contains a polyhistidine tag, a maltose-binding protein (MBP) tag, and a tobacco etching virus (TEV) protease recognition site. This plasmid was transformed into Escherichia coli BL21 (DE3) Codon Plus cells. Cells were cultured at 37°C in LB medium containing 50 mg / ml kanamycin; when the OD600 reached 0.8, 0.5 mM IPTG was added, and the cells were subsequently cultured at 15°C for 15 hours. Cells were harvested by centrifugation at 7,500 × g for 10 minutes. The collected pellet was resuspended in lysis buffer (20 mM Tris-HCl pH 7.3, 300 mM NaCl, 5% glycerol, 0.5% Triton X-100) and sonicated. The lysate was centrifuged at 36,000 × g for 1 hour. The supernatant, after removing cell debris, was loaded onto amylose resin (NEB), and the bound proteins were eluted with 20 mM maltose. The eluted proteins were diluted to a final salt concentration of 50 mM NaCl and purified using an anion exchange column (HiTrap Q HP, 1 × 5 ml, GE Healthcare Life Sciences) equilibrated with 20 mM Tris-HCl pH 7.3, 50 mM NaCl, 2.5% glycerol, and 0.03% Triton X-100. Protein elution was performed using a salt concentration gradient from 50 mM to 1 M NaCl. Subsequently, further purification was carried out using a HiLoad 16 / 600 Superdex 200 prep-grade column, with the storage buffer being 20 mM Tris-HCl pH 7.3, 300 mM NaCl, and 2.5% glycerol.A plasmid expressing the full-length WDR5 protein was obtained from Addgene (#29759, #59974).

[0324]

[0325] Cellular Thermal Variation Analysis (CETSA)

[0326] HEK293T cells were treated with 5 μM UNI418 1 hour prior to harvest. The cells were recovered, washed with PBS, and resuspended in PBS. Equal volumes of the cell suspension were divided into microcentrifuge tubes and heated at the indicated temperature for 3 minutes to denature and precipitate the target protein. The heated samples were immediately flash-frozen in liquid nitrogen. After two freeze-thaw cycles, the tubes were briefly vortexed, and the resulting cell lysates were applied to SDS-PAGE.

[0327]

[0328] Detection of Inositol Phosphate Using High Performance Liquid Chromatography

[0329] 1 × 10⁶ RPE-1 cells for HPLC analysis 5 60 μCi per 60 mm dish [ 3[H] Myo-inositol (NET1177001MC, PerkinElmer) was treated. After 3 days, soluble inositol polyphosphate was extracted from RPE-1 cells and analyzed. Intracellular inositol phosphate was extracted with acid extraction buffer (1 M HClO4, 3 mM EDTA, 0.1 mg / ml IP6) and then neutralized with neutralization buffer (1 M K2CO3, 3 mM EDTA). The lysate was centrifuged for 10 minutes, and the soluble fraction was separated by HPLC. The lipid pellet was dissolved overnight in NaOH containing 0.1% Triton X-100. Each fraction was mixed with Ultima-Flo AP liquid scintillation cocktail (6013599, PerkinElmer), and radioactivity was measured using a scintillation counter. The amount of inositol phosphate was presented as total lipid content or total count / min (CPM) normalized by the inositol coefficient.

[0330]

[0331] Immunofluorescence and EdU labeling

[0332] RPE1 cells were seeded onto 8-well chamber slides (Lab-Tek) and cultured for one day. Cells were treated for 18 hours in the presence or absence of 0.5 μM UNI418, and S-phase cells were labeled by additional treatment with 10 μM EdU for 20 minutes prior to fixation. To visualize chromatin-binding proteins via immunofluorescence, drug-treated cells were washed with PBS and then permeabilized for 10 minutes at room temperature in CSK buffer containing 0.5% Triton X-100 (10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA pH 7.5). Subsequently, cells were fixed with 4% paraformaldehyde and then treated in 100% methanol at -20°C for 10 minutes. After fixation, EdU incorporation was detected using the Click-iT EdU Imaging Kit according to the manufacturer's instructions. Subsequently, cells were blocked with 5% FBS and incubated overnight at 4°C with the primary antibody. After washing three times with 0.1% Tween 20 containing PBS (PBS-T), the cells were incubated with the fluorescently conjugated secondary antibody (Invitrogen) at room temperature for 1 hour. Nuclei were counterstained with DAPI contained in permanent mounting medium (Vector Laboratories). Images were acquired using an LSM 880 confocal microscope (Carl Zeiss). In experiments involving EdU labeling, only EdU-positive nuclei were included for downstream quantitative analysis, as described in the drawing description.

[0333]

[0334] Measurement of DNA DSB repair frequency

[0335] A GFP-reporter assay was performed to evaluate the frequency of DNA DSB repair. As previously described, U2OS cell lines with stably integrated reporter constructs (DR-GFP for HR, EJ5-GFP for NHEJ, provided by Dr. Jeremy Stark) were used. For the assay, 5 × 10⁶ 4 Canine cells were seeded into each well of a 12-well plate with 1 ml of complete medium. After 12 hours, the cells were transfected with 0.5 μg of the I-SceI expression plasmid (pCAG-I-SceI) along with 3 μl of Lipofectamine 3000 (Invitrogen). Six hours after transfection, the medium was replaced with fresh medium containing UNI418. GFP-positive cells were quantified using a flow cytometer with a Becton Dickinson FACSVerse two days after transfection.

[0336]

[0337] Cell viability assay

[0338] 4 × 10 in each well of a 96-well plate 3 After seeding the cells, the compounds at the indicated concentrations were treated for 72 hours. Cell viability was measured using the CellTiter-Glo assay kit (Promega) according to the manufacturer's instructions. The signal was measured by luminescence using a Synergy NEO2 Hybrid Multi-Mode Reader (Biotek).

[0339]

[0340] Annexin V / PI dye assay

[0341] Cells were harvested and resuspended in Annexin-binding buffer. The resuspended cells were immediately incubated with Annexin V-Alexa Fluor 488 and propidium iodide at room temperature for 15 minutes. Cell death was analyzed using Becton Dickinson FACSVerse.

[0342]

[0343] siRNA

[0344] All siRNA oligonucleotides were purchased from Bioneer, Genolution, or Sigma-Aldrich. These siRNAs were transfected into cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. The siRNA sequences used are presented in Figure 42.

[0345]

[0346] Immunoprecipitation

[0347] HCT116 cells were transfected with a vector encoding FLAG-WDR5 and cultured for 24 hours. 10 μM of MG132 (Sigma Aldrich, C2211-5 mg) was added for 3 hours, and cells were harvested 24 hours after transfection. Whole cell lysates were prepared by lysing cells in Buffer X [100 mM Tris-HCl (pH 8.5), 250 mM NaCl, 1 mM EDTA, 1% NP40, 5 mM MgCl2] supplemented with a protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific) and 50 units of Benzonase, and incubated at 4°C for 1 hour. The lysates were purified by centrifugation at 15,000 × g at 4°C for 10 minutes. FLAG-tagged proteins were reacted with anti-FLAG M2 agarose-affinity beads (Sigma Aldrich) by spinning at 4°C for 1 hour. The beads were washed three times with Buffer X and eluted with Buffer X containing 0.15 mg / ml FLAG peptide. Co-immunoprecipitated proteins were loaded onto SDS-PAGE and analyzed by immunoblotting. Proteins were detected using a ChemiDoc MP imaging system (Bio-Rad).

[0348]

[0349] Mouse experiment

[0350] 6-week-old NOD.CB17-Prkdc scid The male mouse was purchased from Orientbio.

[0351] Mice were reared under 12-hour light and dark cycles in a specific pathogen-free environment with an indoor temperature of 22 ± 2°C and relative humidity of 40-60%.

[0352] To induce subcutaneous human colorectal cancer xenograft, 1 × 10 6 HCT116 PARP1 + / + or PARP1 - / - The cells were mixed with 200 μl of 50% Matrigel (#354234, Corning) and injected into the right flank of each mouse.

[0353] Tumors formed on day 20 after injection, and were subsequently randomized into four groups for treatment (n>3 per group).

[0354] Tumor size was measured before treatment, and it was confirmed that there was no clear difference in size between the groups (tumor size > 0.5 cm).

[0355] Mice were subcutaneously injected with vehicle (a solution of NMP, PEG300, and 30% water-soluble hydroxypropyl-β-cyclodextrin solution mixed in a 1:4:5 volume ratio, 4 ml / kg), UNI418 (10 mg / kg), olaparib (50 mg / kg), or UNI418 + olaparib every other day.

[0356] All mice were sacrificed after 12 days, and tumors were excised to measure size and weight and photographed. There were no significant differences in the body weight of all mice.

[0357] All animal experiments were approved and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Ulsan National University of Science and Technology (UNIST).

Claims

1. A 4-aminoquinazoline derivative compound represented by the following chemical formula 1 or a pharmaceutically acceptable salt thereof: <Chemical Formula 1> .

2. An antiviral agent comprising the compound of claim 1.

3. An antiviral agent according to paragraph 2, characterized in that the compound inhibits SARS-CoV-2 infection.

4. An antiviral agent according to paragraph 2, characterized in that the compound is a dual inhibitor of PIKfyve and PIP5K1C.

5. A pharmaceutical composition for treating cancer or tumors comprising the compound of claim 1.

6. A pharmaceutical composition for treating cancer or tumors according to claim 5, characterized in that the cancer is a DNA repair-dependent cancer.

7. A pharmaceutical composition for treating cancer or tumors according to claim 5, characterized in that the tumor is a BRCA dysfunction tumor or a PARP inhibitor-resistant tumor.

8. A pharmaceutical composition for treating cancer or tumor according to claim 5, characterized in that the cancer or tumor is one selected from the group consisting of BRCA-mutated cancer, BRCA-deficient tumor, and PARP1-deficient tumor.

9. A pharmaceutical composition for treating cancer or tumors, characterized in that, in claim 5, the compound is administered in combination with a PARP inhibitor.

10. A pharmaceutical composition for treating cancer or tumors according to claim 5, characterized in that the cancer is breast cancer and ovarian cancer.

11. A pharmaceutical composition for treating cancer or tumors, characterized in that, in claim 5, the tumor is a colon tumor.